Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 6 times upper limit of normal (ULN); obtained within 14 days prior to study entry
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times institutional upper limit of normal with or without liver metastasis, within 21 days prior to study entry
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) no greater than 3.0 times the upper limit of normal
Serum transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) less than three times the upper limits of normal (ULN)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 1.5 times the upper limit of normal
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 times upper limit of normal as per local laboratory. Additional inclusion required for donor arm participants to proceed with transplant
Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 times the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 4 times the upper limit of normal (unless clinically considered to be related to liver involvement with leukemia)
Have an alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level ?5 times upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal; for patients with documented liver metastases, AST/ALT =< 5.0 times the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal
TREATMENT INCLUSION: Aspartate aminotransferase (AST) 3 times or less than the upper limit of normal
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ? 2.5 times upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 times the upper limit of institutional normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 times upper limit of normal (ULN)
Clinically significant hepatic dysfunction (alanine or aspartate aminotransferase > 7 times the upper limit of normal)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3.0 times upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than 2.5 times the upper limit of normal
AST (aspartate aminotransferase) and ALT (alanine aminotransferase) < 3 times upper limit of normal (ULN)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal at the screening visit
Aspartate aminotransferase (AST) ? 3 times the upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less or equal to 2.5 times the upper limit of normal
Aspartate and alanine aminotransferase (AST or ALT) =< 2 times the upper limit of the reference range
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than five times the upper limit of normal
TREATMENT WITH SJCAR19: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 5 times the upper limit of normal for age
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 5 times upper limit of normal (ULN)
Hepatic impairment as defined by alanine transaminase (ALT) or aspartate aminotransferase (AST) levels greater than 2 times the upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than five times the upper limit of normal
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal at the screening visit
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (within 16 days before starting therapy)
Liver transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) greater than 3 times the upper limit of normal
Serum alanine aminotransferase (ALT)/alanine aminotransferase (AST) =< to 2.5 times the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times the upper limit of normal; for patients with documented liver metastases, AST/ALT =< 5.0 times the upper limit of normal
Patients must have normal hepatic function (bilirubin, aspartate aminotransferase [AST] and alanine aminotransferase [ALT] < 2 times the upper limit of normal)
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within 5 times the upper limit of normal and a total serum bilirubin of less than 3 times the upper limit of normal, both of which define the upper limit of grade 2 treatment related toxicities
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times the institutional upper limits of normal.
Aspartate aminotransferase (AST) greater than 2.5 times the upper limit of normal
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less or equal to 3 times the upper limit of the institutional normal unless liver involvement by malignancy is demonstrated
Hepatic: Active hepatitis (alanine aminotransferase [ALT], aspartate aminotransferase [AST], or bilirubin > 2 times the upper limit of normal [ULN]) or evidence of moderate to severe periportal fibrosis by liver biopsy
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) must be <= 2.5 * the upper limit of the normal range. AST and ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the presence of metastatic disease in liver.
Obtained =< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 times upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times upper limit normal
Serum alanine aminotransferase or aspartate aminotransferase < 3 times the upper limit of normal (ULN)
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 times the upper limit of normal
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase < 3 times upper limit of laboratory normal
Aspartate aminotransferase (ALT)/alanine aminotransferase (AST) =< 2.5 times the upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal if no liver involvement or =< 5 times the upper limit of normal with liver involvement
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 times the upper limit of normal
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 5 times the upper limit of normal for age
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less or equal to 3 times the upper limit of the institutional normal unless liver involvement by malignancy is demonstrated
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Aspartate aminotransferase (AST) of =< 3 times upper limit of normal
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 times the upper limit of normal
Aspartate aminotransferase (AST) < 5 times the upper limit of normal
Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times the institutional upper limits of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Patients must have an alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the institutional upper limits of normal
If the research participant is to undergo leukapheresis, he/she must have alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the institutional upper limits of normal\r\n* Note: in the event a patient has elevated levels of liver enzymes possibly related to underlying disease, the patient will still be considered eligible
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Aspartate aminotransferase (AST) /alanine aminotransferase (ALT) =< 3 times upper limit of normal, unless these are thought to be due to AML
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times upper limit of normal (UNL)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) are equal or greater than 2 times the upper limit of normal (ULN)
Aspartate aminotransferase (AST) < 5 times the upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3.5 times the upper limit of normal in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert’s), within 14 days prior to starting therapy
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times the upper limit of normal
RECIPIENT: Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 times upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 times the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 times upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 times normal
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (ULN)
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal (ULN)
Have an alanine aminotransferase (ALT)/aspartate aminotransferase (AST) level ?5 times upper limit of normal (ULN)
Patients with alanine aminotransferase (ALT)/aspartate aminotransferase (AST) > 3 times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's disease
Aspartate aminotransferase (AST) 3 times or less than the upper limit of normal
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 1.5 times the upper limits of normal within 7 days prior to starting treatment in the absence of liver metastasis; in the presence of liver metastasis serum AST and ALT less than or equal to 5.0 times the upper limits of normal within 7 days prior to starting treatment
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) must be no more than 2.5 times upper limit of normal unless due to disease involvement of the liver
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 3.5 times the upper limit of normal
Aspartate aminotransferase (AST) < 2.5 times upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 times upper limit of normal
Within 14 days prior to step 1 registration: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 times institutional upper limit of normal
Liver disease: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limits of normal, unless determined to be a result of the primary hematologic malignancy
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 3 times upper limit of institutional normal
Creatinine within normal institutional limits OR creatinine clearance > 60 mL/min/1.73 m^2 for subjects with above normal aspartate aminotransferase (AST) and alanine aminotransferase (ALT) with alkaline phosphatase within < 1.5 times upper limit of normal
Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 times the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times institutional upper normal level (AST and ALT =< 5 times institutional upper normal level, if there is evidence of liver metastasis)
AST (aspartate aminotransferase) and ALT (alanine aminotransferase) < 3 times upper limit of normal (ULN)
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less or equal to 2.5 times the upper limit of the institutional normal
Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 times the upper limit of normal (ULN) within 14 days prior to admission
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 times institutional upper limit of normal (IULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 times the institutional upper limit of normal
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within 5 times the upper limit of normal
Aspartate aminotransferase (AST) less than 5 times the upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 3.5 times the upper limit of normal
Aspartate aminotransferase (AST) < 2.5 times upper limit of normal
Aspartate aminotransferase (AST) =< 3.0 times upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 times the upper limits of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 times upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must each be =< 3-times the upper limits of normal (ULN) or =< 10-times normal if due to ATL
Aspartate aminotransferase (AST) less than 5 times the upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than 2 times the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times upper limit of normal
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times upper limit of normal; values above these levels may be accepted, at the discretion of the PI or LAI, if such elevations are thought to be due to liver involvement by malignancy or GVHD
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = < 2.5 times upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times upper limit of normal
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 times the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times above the upper limits of the institutional norm; ALT, AST can be < 5 times upper limits of normal if patients have hepatic involvement
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than three times the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times the upper limit of normal
Aspartate aminotransferase (AST) =< 2.5 times the UIHC upper limit of normal
Aspartate aminotransferase (AST) 3 times or less than the upper limit of normal
Have adequate hepatic function (bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT), defined as ? 2 times the upper limit of normal [ULN])
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) within 3 times the upper limits of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (within 16 days before starting therapy)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 times the upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 times the upper limit of normal
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 1.5 times the upper limits of normal; note: if hepatic function is abnormal, the decision to initiate temozolomide treatment should carefully consider the benefits and risks for the individual patient
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 times the upper limit of normal
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal
Serum alanine aminotransferase or aspartate aminotransferase < 3 times upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 2.5 times upper level of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the institutional upper limit of normal within 4 weeks of enrollment
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times institutional upper limit of normal or =< 5 times institutional upper limit of normal in the presence of liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 times institutional upper limit of normal or =< 5.0 times institutional upper limit of normal in the presence of liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times above the upper limits of the institutional normal (norm)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (within 16 days before starting therapy)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 times normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times the institutional upper limit of normal
Patients must have the following screening results for hepatic function according to MD Anderson testing standards: total bilirubin < 1.5 times the upper limit of normal; alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST - if available) must be < 2 times the upper limit of normal
Alanine aminotransferase (ALT) and aspartate transaminase (AST) less than or equal to 3 times the upper limit of the institution-established normal range
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
Aspartate aminotransferase (AST) and alanine transaminase (ALT) < 2 times the upper limit of normal
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 times the upper limit of normal (ULN)
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than or equal to 5 times the upper limit of normal
Liver transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) less than 10 times the upper limit of normal (unless due to active myositis)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times the upper limit of laboratory normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 times the upper limit of normal
Aspartate aminotransferase (AST) =< 2 times upper limit of normal
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) less than 2.5 times the upper limit of normal without evidence of active infectious hepatitis
Aspartate aminotransferase and/or alanine transaminase >5 times upper limit of normal.
Total bilirubin or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? 2.5 times upper limit of normal (ULN) at screening.
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5.0 times the upper limit of normal unless hepatic dysfunction is related to liver involvement with disease
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 times the upper limit of normal (ULN)
Aspartate aminotransferase or alanine aminotransferase > 3 times the upper limit of normal.
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 times the upper limit of normal (ULN)
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 2.5 times the upper limit of normal; in patients with liver metastasis, liver function tests should be < 5 times the upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less or equal to 2.5 times the upper limit of normal
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 1.5 times the upper limits of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 3 times the upper limit of the institution-established normal range
Aspartate aminotransferase (AST) < 2 times the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >= 2.5 times the upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times institutional upper normal level (AST and ALT =< 5 times institutional upper normal level, if there is evidence of liver metastasis)
Transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) < 2 times upper limit of normal values
Total bilirubin (TBL), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than three times the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal if no liver involvement or =< 5 times the upper limit of normal with liver involvement
Serum total bilirubin less than 2.5 mg/dl, and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values less than or equal to 2.5 times the upper limit of normal; ALT and AST values above these levels may be accepted (up to a maximum of 5 times the upper limit of normal), at the discretion of the principal investigator (PI) or study chairperson, if such elevations are thought to be due to liver involvement by malignancy
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
Patients with history of severe liver disease, defined as and confirmed by elevated alanine aminotransferase\r\n(ALT) and aspartate aminotransferase (AST) greater than 1.5 times the upper limit of normal.
Is known or suspected to have significant hepatic dysfunction, with aspartate aminotransferase (AST) & alanine aminotransferase (ALT) 3 times above upper limit of normal (ULN) per institutional laboratory
Patients with severe hepatic impairment as defined as aspartate aminotransferase (AST)/alanine aminotransferase (ALT) greater than three times the upper limit of normal and/or, total bilirubin greater than 3 mg/dL, and/or Child-Pugh score > 9
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values greater than 5 times the upper limit of normal
Serum aspartate aminotransferase (AST) =< 1.5 times the upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 10 times institutional upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times the upper limit of normal
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 times the upper limit of normal
The screening results for aspartate aminotransferase (AST), if available, must be < 2 times the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be < 3.0 times the upper limit of the institutional normal range; test results must be no more than 3 months old
Alanine aminotransferase (ALT) must be < 2 times the upper limit of normal; if available, screening results for aspartate aminotransferase (AST) must be < 2 times the upper limit of normal
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) lower than three times the upper\r\nlimit of normal
Minocycline trial only: screening results for aspartate aminotransferase (AST) must be < 3 times the upper limit of normal
Patient with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) three times the upper limit of normal
An aspartate aminotransferase (AST) less than 2 times the upper limit of normal, unless these values are due to underlying hematologic malignancy
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 times the upper normal limit
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be < 2 times the upper limit of normal, as evidenced in laboratory values =< 3 months old
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 times upper limits of normal prior to chemotherapy
DONOR: Active liver disease (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] levels > 2 times the upper limit of normal [ULN])
Subjects with moderate or severe liver dysfunction at baseline, defined as aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than 5 times the upper limit of normal (ULN)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 times upper limit of normal (ULN)
Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 times upper limit of institutional normal
Transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) < 2 times upper limit of normal values
Transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) < 2 times upper limit of normal values
Aspartate aminotransferase < 3 times upper limit of normal value
Transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) < 3 times upper limit of normal values
Liver transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) greater than 3 times the upper limit of normal
Liver transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) greater than 3 times the upper limit of normal
Liver transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) greater than 3 times the upper limit of normal
Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)
Transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) =< 2.5 x institutional upper limit normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Obtained =< 48 hours prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 1.5 x the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limits of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal for age
Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ? 3.0 x upper limit of normal (ULN)
INCLUSION CRITERIA FOR SECOND-LINE THERAPY: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X the upper normal limit of institution's normal range
Subject has a total bilirubin ? 1.5 x upper limit of normal (ULN), albumin ? 2.5 g/d, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × upper limit of normal (ULN);
Aspartate aminotransferase and alanine aminotransferase ?3 x upper limit of normal (ULN)
Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ?2.5 upper limit of normal (ULN).
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal range
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3X upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 5 x upper limit normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN)
Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) ? 10 x upper limit of normal for age
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x the institutional upper limit of normal (IULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/alkaline phosphatase: =< 2.5 x upper limit of normal (ULN)
Patients without underlying liver disease\r\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X institutional upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5 x the upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.0 x upper limit of institutional normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the institutional upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2 x upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase, (ALT) =< 3.0 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of reference range
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limits of normal
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 5.0 x upper limit of normal (ULN).
Serum alanine aminotransferase (ALT) or aspirate aminotransferase (AST) must be < 2.5 x upper limit of normal (ULN)
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 5.0 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal range
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 2x upper limit of normal (ULN) compatible for surgery
STRATUM A: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN); for the purposes of eligibility the ULN of ALT and AST is 45 U/L
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 5X upper limit of normal (UNL);
Obtained within 21 days prior to cycle 1, day 1: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): =< 3 x upper limit of normal (ULN)
(ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limits of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN), within 2 weeks of registration
Obtained within 28 days prior to registration: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) with alkaline phosphatase =< 2.5 x ULN OR
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x institutional upper limit of normal (ULN), unless felt to be due to disease involvement
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 X upper limit of normal
Within 4 weeks before enrollment: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 5.0 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 x upper limit of normal as per local laboratory
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) within 14 days of registration
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of institutional normal (within 14 days of study registration)
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 2.5 x upper limit of institutional normal reference range
No more than 14 days prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 X upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST)/bilirubin =< 5 X upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal, within 2 weeks of registration (except where specified otherwise)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) within 14 days prior to first dose
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal obtained < 4 weeks prior to starting treatment
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of institutional normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? 5 x institution’s upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of institutional normal
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) >= 2.5 x upper limit of normal
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x upper limit of institutional normal (ULN), within 14 days of study registration (within 30 days for pulmonary and cardiac assessments)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 2.5 x upper limit of institutional normal reference range
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 1.5 X the upper limit of normal
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) >= 2.5 upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the upper limit of normal
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) above 2.5 upper limit of normal (ULN)
Aspartate aminotransferase(AST) and alanine aminotransferase (ALT) < 5 x upper limit of normal and bilirubin < 3 x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3x upper limit of normal
DONOR: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x institutional upper limit of normal
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) must be < 5 x upper limit of normal unless related to disease
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >= 6 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of institutional normal
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3 x upper limit of normal range
Aspartate aminotransferase (AST)/alanine aminotransferase (alanine transaminase) (ALT) < 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X upper limit of normal
Within 14 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x the upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 X upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.0 x upper limit of normal (ULN)
Within 6 weeks of day 1: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) all =< 2.5 x the institutional upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) must be < 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal for age (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 X the upper limits of normal
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x the upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.6 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) for the laboratory
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x upper limit or normal (ULN) (stenting to improve biliary obstruction is permitted)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < or =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limits of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal obtained no more than 28 days prior to the start of neoadjuvant endocrine therapy
Aspartate aminotransferase (AST), and/or alanine aminotransferase (ALT) > 2 x the upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 5 × the upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 3 x the upper limit of normal
Aspartate aminotransferase/alanine aminotransferase of =< 2.5 × upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< twice the upper limit of normal
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3 x upper limit of normal range
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) obtained within 2 weeks prior to registration
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x the upper limits of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x the upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 10x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limits of normal
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) for the laboratory
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 X the upper limit of institutional normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of normal) are not permitted
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 x the upper limit of normal
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 3.0 x the institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 X the upper normal limit of institution's normal range
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
Adequate hepatic function with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal for age
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limits of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 5 x upper limit of normal
Bilirubin, aspartate aminotransferase (AST)/alanine aminotransferase (ALT), alkaline phosphatase (ALP) =< 2 x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) (AST and ALT =< 6 x ULN for patients on hyperalimentation for whom these abnormalities are felt to be due to the hyperalimentation)
alanine aminotransferase (ALT) and aspartate transaminase (AST) ? 3.0 × upper limit of the normal (ULN),
Aspartate aminotransferase and alanine aminotransferase ? 3 × upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN), alanine aminotransferase (ALT) < 3 x ULN
Aspartate aminotransferase AST, alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ? 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x upper limit normal (ULN)
Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) > 2.5 x upper limit of normal (ULN).
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x the upper limit of normal.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X the upper normal limit of institution's normal range
Within 14 days of study registration (30 days for pulmonary and cardiac): aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of institutional normal
Obtained within 28 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal, unless bone or liver metastasis is present (=< 5 x upper limit of normal)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 X institutional upper limit of normal
Subjects with aspartate aminotransferase (AST) or alanine transaminase (ALT) >= 2 x upper limit of normal (ULN)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 upper limit of normal (ULN)
Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) < 2 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 X upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 × the upper limit of normal (ULN).
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limits of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal
Hepatic enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) =< 2.5 x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limits of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal (ULN) within 2 weeks before baseline
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< or = 2.5 X institutional upper limit of normal (ULN).
Transaminases (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) =< 3.0 x upper limit of normal (ULN) unless due to leukemia infiltration
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x the upper limit of normal, within 14 days prior to registration
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal value (unless elevation is determined by the treating physician to be related to involvement by underlying cancer)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of less than 3 X institutional upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of less than 3 X institutional upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limits of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limits of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >= 3 x laboratory upper normal limits
Serum aspartate aminotransferase and alanine aminotransferase ? 2.5 x upper limit of normal (ULN)
Alanine transaminase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3.0 x upper limit of normal (ULN);
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.0 * upper limit of normal (ULN).
Serum aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) > 2.5 × upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x upper limit normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x institutional upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3.0 × the upper limit of normal (ULN).
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to (<=) 2.5*the upper limit of normal (ULN);
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5X institutional upper limit of normal
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3x upper limit of normal
Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 5 x the institutional normal upper limit
Platelet Count ? 50 x 10^9/L (? 100 x 10^9/L if aspartate aminotransferase [AST] or alanine aminotransferase [ALT] is ? 2 x the upper limit of the normal range [ULN]) in the absence of platelet transfusion(s) or thrombopoietin mimetics in the prior 7 days
Aspartate aminotransferase (AST) or alanine aminotransferase (AST) =< 2.5 x upper limits of normal except if due to disease infiltration of the liver
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 3 x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT ) =< 2 x upper limit of normal (ULN)
Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT) less than or equal to 5 X the upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN) obtained within 4 weeks prior to registration
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x the upper limit of normal
Serum alanine aminotransferase (ALT)/serum aspartate aminotransferase (AST) < 2.5 X ULN (the upper limit of normal)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (unless the transaminitis is considered to be related to MF)
(ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 upper limit of normal or > 250 U/l
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 X upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limits of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper normal limit (=< 5 x upper normal limit if documented hepatic involvement with lymphoma)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 3 x upper limit of normal
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN)
Transaminases (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) =< 2.0 x upper limit of normal (ULN)
Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) < 2 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are present
Aspartate aminotransferase/alanine aminotransferase (AST/ALT) > 5 x upper limits of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x the upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x the upper limit of the normal range within 21 days prior to study registration
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 5 x upper limit normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x institutional upper limit of normal (IULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 upper limit of normal within 30 days prior to registration
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)
Alanine aminotransferase and aspartate aminotransferase ?2.5 x the upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.0 x upper limit of normal
alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 4x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 2.5 X the upper limit of normal
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) and/ or alanine aminotransferase (ALT) should be =< 2 x upper limit of normal (ULN, defined as per laboratory where blood testing is done)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must each be =< 2.5 x the upper limits of normal
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN)
Have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 1.5 X upper limit of normal (ULN)
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x institutional upper limit normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x the upper limit of normal within 30 days prior to registration
Alanine aminotransferase and/or aspartate aminotransferase ?2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 institutional upper limit of normal (ULN)
Alanine transaminase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x institutional upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) (must be within 7 days of MLA)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 6 x upper limits of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) below the institutional upper limits of normal
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 5 x upper limit of normal
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 X upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal OR two downtrending values
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 6 x upper limits of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) + alanine aminotransferase (ALT) > 2 upper limits of normal value
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN; concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of normal) are not permitted
Within one week of study entry: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal, OR two consecutive downtrending values for patients who have undergone biliary stenting
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN; concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of normal) are not permitted
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.0 x upper limits of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal OR 5 x upper limit of normal (ULN) for patients status post (s/p) biliary stenting AND decreasing for at least two time points after stenting
Within 14 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal range
Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) >3x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x upper limit of normal
Aspartate aminotransferase/alanine aminotransferase (AST/ALT) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Adequate hepatic and renal function laboratory values within 14 days prior to registration: Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x the upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2 × institutional upper limit of normal (ULN)
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 X upper limit of normal (ULN) (part 1 & 2)
alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 3.0 x the institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN) for age
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) and/or alkaline phosphatase =< 3 X the upper normal limit of institution's normal range
Aspartate aminotransferase (AST) less 5x normal and alanine aminotransferase (ALT) 5x normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X normal institutional limits
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) unless considered to be the result of leukemic involvement by the principal investigator (PI)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =< 2.5 x the upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) >= 3 x upper limit of normal
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper normal limit (=< 5 x upper normal limit if documented hepatic involvement with lymphoma)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) within 14 days prior to registration
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Bilirubin <2 x upper limit of normal (ULN) and aspartate aminotransferase (AST), alanine aminotransferase (ALT) <3 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal range (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5x the upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 5 x upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): =< 2.5 x institutional upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >2 × upper limit of normal (ULN),
Aspartate aminotransferase (AST) =< 5 x the upper limit of normal; alanine aminotransferase (ALT) =< 5 x the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
Alanine aminotransferase (ALT) less than 3 X upper limit of normal, aspartate aminotransferase (AST) less than 3 X upper limit of normal
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 5 x upper limit of normal, and
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN)
Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) >1.5 x Upper limit of normal (ULN).
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x the upper limits of normal
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 x institutional upper limit normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 3 × the upper limit normal (ULN) for the institution (>= 5 × if due to hepatic involvement by tumor)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x upper limit of normal
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =< 2.5 x the upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 4.0 x upper limit of normal; this requirement reflects the excretion of CPX-351 by the liver
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate Aminotransferase (AST) and Alanine transaminase (ALT) < 5.0x the upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) within =< 3 x upper limit of normal
Aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN) and alanine aminotransferase (ALT) =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 1.5 x upper limit of normal (ULN)
Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 10 × upper limit of normal
Aspartate aminotransferase or alanine aminotransferase > 2.5 x upper limit of normal.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limits of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) AND aspartate aminotransferase (AST) < 3 × upper limit of normal.
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 2.5 the upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3.0 x upper limits of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 1.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 x the upper limit of normal (ULN) for the laboratory (lab) being used
Aspartame aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
Obtained =< 30 days prior to registration: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the upper limit of normal
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 x institutional upper limit of normal (IULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 2.5 upper limit of normal (ULN)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x the upper normal limit
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5.0 x upper limit of normal as evidenced by impairment of baseline laboratory values
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X upper limit of normal (ULN)
Significant hepatic (serum aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] > 3 time upper limit of normal institutional normal), gastrointestinal, or biliary disorders that could impair absorption, metabolism, or excretion of orally administered medications
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both within 3 x upper limit of normal based on institutional values
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 20 x upper limit of normal (ULN) or
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5.0 x upper limit of normal (ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 5 x upper limit of normal
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 x the upper limit of normal
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3.0 x upper limit of normal (ULN)
Transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 1.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (CTCAE grade 2)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Aspartate Aminotransferase (AST) and Alanine transaminase (ALT) <10x upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 x the upper normal limit
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >= 3 x of the upper limits of normal
Individuals with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x normal upper limit any time during the previous 2 months
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2 x upper limit of normal
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) greater than 2.5 x upper limits of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3.0 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) within normal institutional limits
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal, unless attributed to tumor, obtained within 2 weeks prior to registration
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal unless the liver is involved with tumor, in that case, AST and ALT must be =< 5 x upper limit of normal
Greater than 3 x the upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal unless the liver is involved with tumor, in that case, ALT/AST must be =< 5 x upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) at screening > 3x upper limit of normal (ULN)
Aspartate aminotransferase or alanine aminotransferase at screening >3.0 x upper limit of normal (ULN) unless considered due to leukemic organ involvement
Serum aspartate transaminase (aspartate aminotransferase [AST]) and serum alanine transaminase (alanine aminotransferase [ALT]) =< 2.5 x upper limit normal
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN with metastatic liver disease within 14 days prior to registration.
Alanine transaminase (ALT) < 3.0x the upper limit of normal (ULN)
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3 x ULN (=< 5 x ULN if documented liver metastases are present)
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3 x ULN.
Obtained =< 14 days prior to registration: Aspartate transaminase (AST) =< 3 x ULN (=< 5 x ULN for patients with liver involvement)
Aspartate transaminase (AST /SGOT) and alanine transaminase (ALT/SGPT) ? 3.0 x ULN.
aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) ? 5 times the upper limit of normal (ULN)
Aspartate transaminase (AST), alanine transaminase (ALT) =< 3 × ULN
Hepatic: aspartate transaminase (AST)/alanine transaminase (ALT) ?2.5 x upper limit of normal (ULN); total or conjugated bilirubin ?1.5 x ULN
Aspartate transaminase (AST; SGOT), alanine transaminase (ALT; SGPT) ? 2.5 × ULN, (or ? 5 × ULN if tumor involvement (liver) is present).
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 5 x ULN
Aspartate transaminase (AST) or alanine transaminase (ALT) ? 3 x ULN, unless due to organ leukemic involvement
Alanine transaminase (ALT)/aspartate transaminase (AST) ?2.5 x upper limit of normal (ULN)
Serum aspartate transaminase (AST) or alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN); serum aspartate transaminase (AST) or alanine transaminase (ALT) =< 5 is permissible if due to disease
Adequate hepatic function (total bilirubin ? 1.5 × upper limit of normal [ULN] for the institution; aspartate transaminase (AST) and alanine transaminase (ALT) ? 2.5 × ULN.
Serum aspartate transaminase (AST) or alanine transaminase (ALT) =< 3.0 x upper limit of normal (ULN)
Alanine transaminase (ALT) ? 3 times the ULN, unless determined to be directly due to lymphoma.
Aspartate transaminase (AST) ? 3 times the ULN, unless determined to be directly due to lymphoma
Aspartate transaminase (AST) =< 3 x ULN, except for patients with liver metastasis, who are included if AST =< 5 x ULN, at the screening visit
Aspartate transaminase/alanine transaminase (AST/ALT) ? 2.5 x upper limit of normal (ULN)
Alanine transaminase (ALT) and aspartate transaminase (AST) within 1.5x upper limit of normal;
Aspartate transaminase (AST) =< 3 x ULN
Serum aspartate transaminase (AST) or alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN)
Serum alanine transaminase (ALT) and/or aspartate transaminase (AST) values < 3 x the upper limit of normal (ULN) of the local laboratory reference range
Aspartate aminotransferase (AST)/alanine transaminase (ALT) less than 2.5 X institutional ULN
Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) < 2.5 upper limit of normal (ULN), or AST and ALT < 5 ULN if liver function abnormalities are due to underlying malignancy.
Aspartate transaminase (AST) and alanine transaminase (ALT) levels ? 2.5 × ULN or AST and ALT levels ? 5 x ULN (for subjects with documented metastatic disease to the liver)
Aspartic transaminase (AST) =< 1.5 x upper limit of normal (ULN).
Alanine transaminase (ALT) =< 1.5 x ULN.
Obtained =< 14 days prior to registration: Aspartate transaminase (AST) =< 2 x ULN (=< 5 x ULN for patients with liver involvement)
Aspartate aminotransferase (aspartate transaminase [AST]) and alanine aminotransferase (alanine transaminase [ALT]) =< 3.0 x ULN for the institution within 14 days of study registration
Aspartate transaminase (AST) or alanine transaminase (ALT) =< 3 x ULN
Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< 5.0 x ULN
Alanine transaminase or aspartate transaminase ? 5 times the ULN
Alanine transaminase (ALT) =< 2.5 x upper normal limit (ULN) (=< 5 x ULN for subjects with documented metastatic disease to the liver).
Serum aspartate transaminase or alanine transaminase =< 3.0 x upper limit of normal (ULN)
Obtained =< 28 days prior to registration: Aspartate transaminase (AST) AND alanine transaminase (ALT) =< 2.5 x ULN
Aspartate transaminase (AST) and alanine transaminase (ALT) ? 2 × ULN except for patients with known liver metastases, in which case aspartate transaminase or alanime transaminase may be ? 5.0 × ULN
Aspartate aminotransferase (aspartate transaminase [AST]) and alanine aminotransferase (alanine transaminase [ALT]) levels ? 2 x institutional upper limit of normal (ULN)
Aspartate transaminase (AST) =< 2.5 x ULN? alanine transaminase (ALT) =< 2.5 x ULN, except for patients with liver metastasis, who are only included if AST and ALT < 5 x ULN
Aspartate transaminase (AST) =< 2.5 x ULN obtained =< 7 days prior to registration
Serum aspartate transaminase (AST) or alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN)
Aspartate transaminase or alanine transaminase ?3 x ULN (?5x ULN in the presence of hepatic metastases)
Aspartate transaminase (AST) and alanine transaminase (ALT) ? 3.0 x ULN within 14 days prior to the first study treatment (cycle 1, day 1) with the following exception:\r\n* Patients with liver involvement: AST and/or ALT ? 5 x ULN
Serum aspartate transaminase (aspartate aminotransferase [AST]) or alanine transaminase (alanine aminotransferase [ALT]) less than or equal to 3 x ULN (unless due to B-ALL)
Serum aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 x upper limit of normal (ULN)
Aspartate transaminase (AST) and alanine transaminase (ALT) ?2.5 times the upper limit of normal (ULN); and
Serum aspartate transaminase (aspartate aminotransferase [AST]) or alanine transaminase (alanine aminotransferase [ALT]) =< 3.0 x upper limit of normal (ULN)
Serum aspartate transaminase (AST) and alanine transaminase (ALT) less than 1.5 times the upper limits of normal
Alanine aminotransferase (ALT) and aspartate transaminase (AST) ? 2.5 × upper limit of the normal reference range (ULN)
Aspartate transaminase (AST) and alanine transaminase (ALT) ?2.5 times the upper limit of normal (ULN); and
Alanine transaminase (ALT) or aspartate transaminase (AST) >= 2.5 x the upper limit of normal (ULN)
Aspartate transaminase (AST) =< 3 x ULN, except with liver involvement by the lymphoma who are only included if AST =< 5 x ULN; alanine transaminase (ALT) < 3.0 x ULN, except with liver involvement by the lymphoma who are only included if AST =< 5 x ULN
Aspartate Transaminase (AST) and alanine transaminase (ALT) =< 2.5 x institutional upper limit of normal (ULN) unless liver metastases are present, in which case it must be =< 5 x ULN
Adequate renal and hepatic function (creatinine ? 2.0 mg/dl, bilirubin ? 2.0 mg/dl, aspartate transaminase (AST) and alanine transaminase (ALT) ? 4X upper limit of normal range).
Serum alanine transferase (ALT) and aspartate transaminase (AST) < 3 the upper limit of normal (ULN); < 5 ULN if there is liver involvement secondary to the tumor
Aspartate transaminase (aspartate aminotransferase [AST]) or alanine transaminase (alanine aminotransferase [ALT]) =< 2.5 x ULN
Liver enzymes: Aspartate transaminase (AST); Alanine transaminase (ALT) or Alkaline phosphatase (ALP) ?2.5 x ULN (or ?5.0 x ULN if liver involvement by primary disease);
Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ? 1.5 x upper limit of normal (ULN) with alkaline phosphatase ? 2.5 x ULN, or AST and ALT ? 5 x ULN if liver function abnormalities are due to liver metastases
alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 x ULN (< 5 x ULN if documented hepatic metastases)
Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) =< 3 x upper limit of normal (ULN)
Alanine aminotransferase and/or aspartate transaminase =< 3.0 x ULN or =< 5.0 x ULN if deemed to be elevated due to leukemia
Alanine transaminase =< 3 x ULN
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 times the upper limit of normal ([ULN]; or 5.0 times the ULN in the setting of liver metastases)
Aspartate transaminase (AST) < 2.0 x ULN, except for patients with liver metastasis, who are only included if AST < 3 x ULN; alanine transaminase (ALT) < 2.0 x ULN, except for patients with liver metastasis, who are only included if ALT < 3 x ULN
Aspartate transaminase (AST) =< 3.0 x ULN, except for patients with liver metastasis, who are only included if AST =< 5 x ULN; alanine transaminase (ALT) < 3.0 x ULN, except for patients with liver metastasis, who are only included if ALT < 5 x ULN
Aspartate transaminase (AST)/alanine transaminase (ALT) =< 2.5 x ULN
alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 x ULN (< 5 x ULN if documented hepatic metastases)
Aspartate transaminase (AST) or alanine transaminase (ALT) =< 2.5 x ULN
Alanine transaminase (ALT) =< 2 times the ULN or aspartate transaminase (AST) =< 2 times the ULN; this value must be obtained within two weeks before protocol entry
Aspartate transaminase (AST)/alanine transaminase (ALT) =< 2.5 upper limit of normal (ULN)
Serum aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 x institutional upper limit of normal (ULN)
Aspartate Transaminase (AST) / Alanine Transaminase (ALT) ? 3 times institutional upper limit of normal (except in patients with leukemic infiltration of liver)
Has the following laboratory parameters within 7 days before baseline (C1D1):Serum creatinine ?2 mg/dL; Total bilirubin ?2.0 mg/dL; Alanine transaminase (ALT) or aspartate transaminase (AST) <3.0×the upper limit of normal (ULN); Left ventricular ejection fraction (LVEF) >40%; Forced expiratory volume in 1 second (FEV1) >60% of predicted.
Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) ?3 x upper limit of normal (ULN)
Aspartate transaminase (AST) ? 2.5 x ULN
Hepatic: bilirubin < 1.5 times the upper limit of normal (ULN); alkaline phosphatase (AP), aspartate transaminase (AST), and alanine transaminase (ALT) < 3.0 x ULN (AP, AST, and ALT < 5 x ULN is acceptable if the liver has tumor involvement).
Adequate hepatic function, defined as serum aspartate transaminase (AST) and alanine transaminase (ALT) < 2.5 x upper limit of normal (ULN), and total bilirubin ? 1.5 x ULN except Gilbert's Syndrome where a direct bilirubin ? 1.5 ULN will be used.
Within 14 days of study drug(s) initiation: Alanine transaminase (ALT) and aspartate transaminase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if known hepatic metastases.
Serum aspartate transaminase (AST) or alanine transaminase (ALT) less than or equal to 3.0 x upper limit of normal (ULN)
Obtained =< 21 days prior to registration: Aspartate transaminase (AST) =< 3 x ULN, =< 5.0 x ULN for patients with metastatic disease to the liver
Aspartate transaminase (AST) and alanine aminotransaminase (ALT) =< 3 x ULN
Aspartate transaminase (AST) =< 3 X ULN unless due to direct lymphoma involvement, and then =< 5 X ULN
Aspartate transaminase (AST) and/or alanine transaminase (ALT) < 2.5 x upper normal limit (ULN)
Serum aspartate transaminase (alanine aminotransferase [ALT]) and/or aspartate transaminase (aspartate aminotransferase [AST]) values < 3 x the upper limit of normal (ULN) of the local laboratory reference range; patients with elevated bilirubin due to Gilbert’s syndrome may be permitted with principal investigator (PI) approval
Aspartate transaminase (AST)/alanine transferase (ALT) < 3.0 ULN
Aspartate transaminase (AST) and/or alanine transaminase (ALT) =< 2.5 x ULN or =< 5 x ULN for patients with liver metastases, obtained =< 14 days prior to registration
Aspartate transaminase (AST) or alanine transaminase (ALT) ? 2.5 x institutional ULN. If liver function abnormalities are due to metastatic disease, patients are eligible provided the ALT and AST are < 5 x ULN
Alanine transaminase (ALT) or aspartate transaminase (AST) ? 2.5 x the upper limit of normal (ULN).
Aspartate transaminase (AST) =< 3 x ULN (obtained =< 14 days prior to registration)
Baseline alanine transaminase (ALT) or aspartate transaminase (AST) > 2 x upper limit of normal (ULN) without known complications of metastatic liver disease or primary hepatic disease (e.g. Cushing’s disease and acromegaly studies)
Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ?2.5×ULN.
Alanine transaminase (ALT) < 2.5 times the ULN
Aspartate transaminase (AST) < 2.5 times the ULN
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 times upper limit of normal (ULN) or =< 5.0 times the ULN in the setting of liver metastases
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN) for the institution
Hepatic: Aspartate transaminase (AST) / Alanine transaminase (ALT) ? 2.5 x upper limit of normal (ULN) (if liver metastases are present, ? 5 x ULN); Total or conjugated bilirubin ? 1.5 x ULN
Aspartate transaminase (AST) < 2.5 x upper limit of normal (ULN) and alanine transaminase (ALT) ? 2.5 × ULN.
Aspartate transaminase (AST) at least 2.5 ULN
Alanine transaminase (ALT) at least 2.5 ULN
Aspartate transaminase (AST) level ? 2.5 x upper limit of normal (ULN) and alanine transaminase (ALT) ? 2.5 × upper limit of normal (ULN). For patients with liver metastases, AST ? 5 ULN, and AST ? 5 ULN may be enrolled if agreed upon by the investigator and medical monitor for the sponsor.
Alanine transaminase (ALT)/aspartate transaminase (AST) ? 2.5 x upper limit of normal (ULN).
Hepatic: aspartate transaminase (AST) / alanine transaminase (ALT) ? 2.5 x upper limit of normal (ULN) (if liver metastases are present, ? 5 x ULN); total or conjugated bilirubin ? 1.5 x ULN
Serum aspartate transaminase (AST) or alanine transaminase (ALT) < 3 x upper limit of normal (ULN)
Alanine transaminase (ALT) or aspartate transaminase (AST) =< 3 x ULN (if liver metastases are present, serum transaminases =< 5 x ULN are permitted)
Aspartate transaminase (AST) < 2.5 x upper limit of normal (ULN) and alanine transaminase (ALT) ? 2.5 × upper limit of normal (ULN).
Serum aspartate transaminase (AST) or alanine transaminase (ALT) =< 3.0 x upper limit of normal (ULN); if considered related to ASM/MCL =< 5 x ULN
Aspartate transaminase (AST) and alanine transaminase (ALT) <= 2.5 times the ULN(or <= 5 times the ULN if liver metastases are present).
Participant has adequate hepatic function [bilirubin within normal limits (WNL), aspartate transaminase (AST) and alanine transaminase (ALT) ? 2.5 times the upper limit of normal (ULN), or ? 5.0 times the ULN if the transaminase elevation is due to liver metastases, and alkaline phosphatase ? 5.0 times the ULN]
Within 14 days of enrollment: Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 x ULN for the institution\r\n* For patients in the metastatic cohort with documented liver or bone metastases: AST and/or ALT =< 5.0 x ULN
Serum aspartate transaminase (AST) or alanine transaminase (ALT) < 3 x upper limit of normal (ULN)
Within 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine transaminase (ALT) =< 3.0 x ULN
Aspartate transaminase (AST) =< 3 times ULN for age obtained =< 7 days prior to registration
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 2.0 x ULN
Aspartate transaminase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in patients with liver metastasis)
Aspartate transaminase (AST) and alanine aminotransferase (ALT) < 3 x ULN
Aspartate transaminase (AST) =< 3 x ULN
Aspartate transaminase (AST) and alanine transaminase (ALT) ? 3 x the upper limit of the normal range (ULN) (? 5 x ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days)
Alanine transaminase (ALT) and aspartate transaminase (AST) =< 2.5 times the ULN
Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) ? 3 x upper limit of normal (ULN)
Serum aspartate transaminase (AST) and alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN)
Alanine aminotransferase and/or aspartate transaminase =< 2.5 x ULN
Aspartate transaminase (AST) and alanine transaminase (ALT) < or equal to 1.5 × upper limit of normal (ULN)
Aspartate transaminase (AST) and alanine transaminase (ALT) ?1.5 × upper limit of normal(ULN), or ? 2.5 × ULN with metastatic liver disease.
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 × the upper limit of normal (ULN), or =< 5 × the ULN in the presence of known liver metastases
Aspartate transaminase (AST) and alanine transaminase (ALT) ? 3 × ULN (? 5 x ULN for subjects with liver metastases)
Adequate clinical laboratory values (i.e., plasma creatinine <= 1.5 x upper limit of normal (ULN) for the institution, bilirubin <=1.5 x ULN, alanine transaminase (ALT) and aspartate transaminase (AST) <= 2.5 x ULN).
Alanine transaminase (ALT) and aspartate aminotransferase (AST) ? 2.5 × ULN.
serum aspartate transaminase or alanine transaminase > 3x upper limit of normal (ULN), except in patients with documented liver involvement by lymphoma
Aspartate transaminase (AST)/alanine transaminase (ALT) =< 2.5 x ULN; unless elevated secondary to lymphoma involvement of the liver
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 2.5 x upper limits of normal (ULN)
Serum aspartate transaminase (aspartate aminotransferase [AST]) or alanine transaminase (alanine aminotransferase [ALT]) >= 3.0 x upper limit of normal (ULN)
Adequate hepatic function (total bilirubin ? 1.5x ULN for the institution; AST [aspartate transaminase] and ALT [alanine transaminase] ? 3x ULN).
Adequate hepatic function (total bilirubin ? 1.5×ULN for the institution; aspartate transaminase and alanine transaminase ? 2.5×ULN, or ? 5×ULN if due to liver involvement by tumor; albumin ? 3 g/dL)
For Cohorts 1 and 2: serum aspartate transaminase (AST) or alanine transaminase (ALT) ?3.0 x upper limit of normal (ULN); for Cohort 3: ALT ?2.5 or AST ?2.5 ULN.
Hepatic: Total conjugated bilirubin ? 1.25 x upper limit of normal (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) < 3 x upper limit of normal (ULN) or < 5 x ULN in the setting of liver metastases
Hepatic: Total bilirubin < upper limit of the normal range (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) ? 3 x ULN
Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) =< 2.5 X upper limit of normal
Total bilirubin ? 1.25 x upper limit of the normal range (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) ? 3 x ULN
Aspartate transaminase (AST) and alanine transaminase (ALT) =< 2.5 x ULN for the institution
Aspartate transaminase (AST)/alanine transaminase (ALT) =< 2.5 x ULN
14. Adequate hepatic function (total bilirubin ? 1.5 x ULN for the institution; aspartate transaminase [AST] and alanine transaminase [ALT] ? 2.5 x ULN).
Liver enzymes [aspartate transaminase (AST), alanine transaminase (ALT)] ?2 x ULN
Adequate hepatic function (total bilirubin ? 1.5x ULN (upper limit of normal) for the institution; AST [aspartate transaminase] and ALT [alanine transaminase] ? 3x ULN, or ? 5x ULN if due to liver involvement by tumor).
Serum aspartate transaminase (AST) >2.5x ULN
Serum alanine transaminase (ALT) >2.5x ULN
Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) < 3.0 x upper limit of normal (ULN) unless due to disease.
Aspartate transaminase (AST) =< 3 x ULN
Serum aspartate transaminase (AST) or alanine transaminase (ALT) 2.5 x upper limit of normal (ULN) if no demonstrable liver metastases or 5 x ULN in the presence of liver metastases
Hepatic: Aspartate transaminase (AST) / Alanine transaminase (ALT) ? 2.5 x upper limit of normal (ULN) (if liver metastases are present, ? 5 x ULN); Total or conjugated bilirubin ? 1.5 x ULN
Part 1 only: plasma total bilirubin <= 1.5 mg/dL, alanine transaminase (ALT) and aspartate transaminase (AST) <= 2.5 X ULN.
Serum aspartate transaminase (AST) and alanine transaminase (ALT) < 3 x upper limit of normal (ULN)
Advanced liver disease, including persistent aspartate transaminase (AST), alanine transaminase (ALT), or total bilirubin value >3 × the upper limit of normal, liver biopsy demonstrating cirrhosis, extensive bridging fibrosis, or active hepatitis.
Alanine transaminase (ALT), Aspartate transaminase (AST), or Creatine kinase (CK) greater than 2 times the upper limit of normal
Alanine Transaminase (ALT) and Aspartate Transaminase (AST) ? 2.5 x ULN (if liver metastases are present, then ? 5 x ULN is allowed)
Aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) ? 5 times the upper limit of normal (ULN)
Aspartate transaminase (AST) and alanine transaminase (ALT) ?2.5 × the upper limit of normal (ULN)
Aspartate transaminase (AST) and alanine transaminase (ALT) ?3 × ULN
Aspartate transaminase (AST) or alanine transaminase (ALT) ?3 x ULN, unless considered due to organ leukemic involvement
Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) =< 2.5 X upper limit of normal
The participant has adequate hepatic function as defined by a total bilirubin ? 1.5 x the upper limit of normal (ULN), and aspartate transaminase (AST) and alanine transaminase (ALT) ? 3 x the ULN (or ? 5 x the ULN in the presence of known liver metastases)
Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) =< 2.5 x upper limit of normal (< 5 X upper limit of normal [ULN] for subjects with liver metastasis)
Hepatic: serum bilirubin less than 2x upper limit of normal for age as per local laboratory) (with the exception of isolated hyperbilirubinemia due to Gilbert's syndrome), alanine transaminase (ALT) and aspartate transaminase (AST) less than 4x upper limit of normal for age (as per local laboratory)
Aspartate transaminase (AST) =< 5 x ULN
Alanine aminotransferase and/or aspartate transaminase < 3.0 x ULN (or < 5.0 x ULN if deemed to be elevated due to leukemia)
Aspartate transaminase (AST) > 3.0 x ULN, except for patients with liver metastasis who are excluded if AST > 5.0 x ULN
Aspartate transaminase (AST) =< 3 x ULN unless due to direct lymphoma involvement, and then =< 5x ULN
Aspartate transaminase (AST) and alanine transaminase (ALT) levels =< 5 x upper limit of normal (ULN)
Aspartate transaminase (AST)/alanine transaminase (ALT) =< 2.5 x ULN
Obtained =< 30 days prior to randomization: Alanine aminotransferase (ALT) or aspartate transaminase (AST) =< 3 x upper limit of normal (ULN)
Serum alkaline phosphatase, aspartate transaminase (AST) and alanine transaminase (ALT) ?2.5 × ULN;
Serum aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 x upper limit of normal (ULN)
Serum aspartate transaminase (AST) and alanine transaminase (ALT) =< 4.0 x upper limit of normal (ULN)
Total bilirubin ?1.5 times upper limit of normal value (ULN), aspartate transaminase (AST) and alanine transaminase (ALT) ?5 × ULN.
Alanine transaminase (ALT) < 5.0 x ULN
Alanine transaminase (ALT) =< 3 x ULN
Significant liver disease as defined as aspartate transaminase (AST) or alanine transferase (ALT) twice than normal
Aspartate transaminase (AST) and alanine transaminase (ALT) £1.5 × upper limit of normal (ULN), or ? 2.5 × ULN with metastatic liver disease
Aspartate transaminase (AST) and alanine transaminase (ALT) ? 2.5 x ULN for age
Baseline safety laboratory abnormalities: ANC (absolute neutrophil Count) < 1000 cells/mm3, platelet count < 25,000 cells/mm3, hemoglobin < 8.0 g/dL, AST (aspartate transaminase) or ALT (alanine transaminase) > 5 x ULN (upper Limit of normal), bilirubin > 2.5 x ULN
c. Aspartate aminotransferase (AST) and alanine transaminase (ALT) ? 3.0 x ULN
Aspartate transaminase (AST) =< 3 x upper limit of normal (ULN) (=< 5 x ULN acceptable for pancreatic subjects with known liver metastasis only)
The participant has adequate hepatic function as defined by a total bilirubin less than or equal to 2 x the upper limit of normal (ULN), aspartate transaminase (AST, SGOT) and alanine transaminase (ALT, SGPT) less than or equal to 3 x the ULN (or less than or equal to 5 x the ULN in the presence of known liver metastases).
The participant has adequate hepatic function as defined by a total bilirubin less than or equal to 2 x the upper limit of normal (ULN), aspartate transaminase (AST, SGOT) and alanine transaminase (ALT, SGPT) less than or equal to 3 x the ULN (or less than or equal to 5 x the ULN in the presence of known liver metastases).
Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) < 2.0 x ULN or ? 5 X ULN for subjects with liver metastases.
Alanine aminotransferase (ALT) > 2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases, or > 5 times ULN in presence of liver metastases
Liver function abnormalities as indicated by ongoing hepatic enzyme elevation (AST or ALT) >2 times upper limit of normal (ULN)
AST less than 5 times the upper limit of normal
Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of > 2 times the upper limit of normal of each institution is required
Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of > 2 times the upper limit of normal of each institution is required
For WM, serum immunoglobulin M (IgM) with a minimum IgM level of ? 2 times the upper limit of normal (ULN).
Direct bilirubin within =< 1.5 times the institutional upper limit of normal (ULN); for patients with known Gilbert syndrome, or if the elevation is believed to be leukemia related, the cut-off of =< 3.0 times the institutional ULN is allowable
INCLUSION - TREATMENT: AST less than 5 times the upper limit of normal
Alanine aminotransferase > 2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or > 5 times the ULN in the presence of liver metastases.
AST/ALT =< 1.5 times upper limit of normal\r\n* If transaminase elevation and/or bilirubin elevation is attributed to the presence of liver metastases, a total bilirubin =< 2.5 times the upper limit of normal and an AST and ALT =< 2.5 times the upper limit of normal are permissible; patients with an elevated bilirubin level that is attributed to an inherited disorder, such as Gilbert’s disease, may be enrolled at the discretion of the principal investigator
ALT and/or AST >2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
total bilirubin < 1.5 X (ULN) ; alanine aminotransferase (ALT), aspartate transaminase (AST) ? 2.5 times the upper limit of normal (ULN) if no liver involvement or ? 5 times the upper limit of normal with liver involvement.
Have adequate organ function, including: Absolute neutrophil count (ANC) at least 1.5 x 109/Liter (L), platelets at least 100 x 109/L, and hemoglobin at least 8 grams/deciliter (g/dL); bilirubin no more than 1.5 times upper limits of normal; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) no more than 2.0 times upper limits of normal; Serum creatinine no more than 1.5 times upper limits of normal or calculated creatinine clearance >45 milliliters/minute (mL/min)
ARM I&II: Transaminases =< times above the upper limits of the institutional normal
REP ELIGIBILITY: Serum ALT and AST less than three times the institutional upper limit of normal
CHEMOTHERAPY/CELL INFUSION ELIGIBILITY: Serum ALT and AST less than three times the institutional upper limit of normal
CHEMOTHERAPY/CELL INFUSION ELIGIBILITY: PT and PTT less than or equal to 1.5 times the institutional upper limit of normal
STUDY TREATMENT: Serum aminotransferase value less than 1.5 times the upper limit of the normal range
Liver aminotransferase levels greater than 3 times the laboratory's upper limit of normal (greater than 5 times the laboratory's upper limit of normal if the liver is known to be involved with tumor)
Transaminase levels </=2.5 times the upper limit of normal (ULN)
Alanine aminotransferase (ALT) >2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
Alanine aminotransferase > 2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or > 5 times ULN in the presence of liver metastases
Transaminases =< 2 times above the upper limits of the institutional normal
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values less than or equal to 2.5 times the upper limit of normal; patients with elevations of ALT or AST up to 10 times the upper limit of normal may be considered for participation if such elevations are thought to be due to liver involvement by malignancy; however, in these latter patients, if AST/ALT do not decrease to less than or equal to 2.5 times the upper limit of normal after induction chemotherapy, eligibility for the transplant (research) phase will be at the discretion of the PI
RESEARCH PHASE INCLUSION CRITERIA: In patients with suspected liver disease, AST and ALT must be =< 2.5 times institutional upper limit of normal (ULN)
Liver function criteria: AST and ALT =< 2.5 times the institutional upper limits of normal
Serum creatinine concentration, 1.5 times greater than the upper limit of laboratory normal ranges (ULN), except if related to ALL/LBL,
transaminases (AST or ALT) levels, 5 times greater than the ULN, except if related to ALL/LBL,
AST less than 5 times the upper limit of normal
Serum alanine transaminase (ALT) less than three times the upper limit of normal (Turnstile II)
AST/ALT ? 2.5 times upper limit of normal (ULN)
Liver enzymes less than three times the upper limit of normal
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values >= 2.5 times the upper limit of normal based on age-specific normal values; if the abnormal liver function is attributable to liver involvement by malignancy, patients may be eligible with serum ALT and AST values up to 5.0 times the upper limit of normal, provided the patient has no evidence of impending hepatic failure (encephalopathy or prothrombin time > 2 times the upper limit of normal)
Screening Laboratory Values Hemoglobin ? 9g/dL White blood cell count ? 3,500 cells/mm3 Absolute neutrophil count ? 1,500 cells/mm3 Total bilirubin ? 2 times upper limit of normal Serum AST and ALT ? 2.5 times upper limit of normal Serum creatinine concentration ? 2mg/mL Pregnancy test: negative for females of childbearing potential
acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range;
AST/ALT ? 3 times institutional upper limit of normal (except in patients with leukemic infiltration of liver)
Evidence of abnormal liver function (serum ALT level(s) > 5 times upper limit of normal at screening or creatinine levels >2 times upper limit of normal at screening);
PT and PTT < 1.25 times the institutional upper limit of normal.
Adequate liver function defined by a bilirubin value ?2 times the upper limit of normal (ULN), and transaminases (AST and ALT) values ?2.5 times ULN
AST and/or ALT ?2.5 times upper limit of normal (ULN)
ALT/AST <2.5 times the upper limit of normal (ULN)
Renal and hepatic function values exceeding 2 times the upper normal value
At least one of the following clinical, laboratory, or imaging parameters:\r\n* Mild or moderate ascites\r\n* Serum bilirubin >= 3 mg/dl but less than 6 mg/dl\r\n* Aspartate aminotransferase (AST) > 5 times upper limit of normal (ULN) but =< 10 times ULN\r\n* Alanine aminotransferase (ALT) > 5 times upper limit of normal (ULN) but =< 10 times ULN\r\n* International normalized ratio for prothrombin time (INR) >1.5 but =< 2.5\r\n* Bland portal vein thrombosis (branch or main)\r\n* Functioning transjugular intrahepatic portosystemic shunt (TIPS) or surgical portosystemic shunt
AST > 10 times upper normal limit
ALT > 10 times upper normal limit
Serum ALT and AST less than three times the institutional upper limit of normal
Dysfunction of liver (ALT/AST > 5 times normal value, or bilirubin > 3 times normal value), or of renal function (creatinine clearance <30ml/min/1.73m2)
AST and ALT ? 2.5 times the upper limit of normal (ULN)
AST and ALT ? 2.5 times the upper limit of normal (ULN)
AST and ALT ? 5 times upper limit of normal (ULN)
Liver transaminases > 5-times the upper limit of normal
Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of >= 2 times the upper limit of normal is required
Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of > 2 times the upper limit of normal of each institution is required
AST ? 2.5 times upper limit of normal (ULN) (? 5 times ULN for patients with liver metastases);
Liver enzymes =< 2 times the upper limit of normal
Total bilirubin =< 1.5 x ULN (except for patients with liver metastases, ALT and/or ALT =< 5 times the upper limit of normal is accepted)
ALT > 2.0 times upper normal limit (unless due to chronic GVHD)
Liver function tests >= 2 times the institutional upper limits of normal
Transaminases < 3 times the upper limit of normal
Hepatic Function: Bilirubin ? 1.5 times institutional normal; SGPT (ALT) < 3 times institutional normal
Patients must have adequate bone marrow function (ANC = or > 1,500/mm^3 and platelet count of = or > 100,000/mm^3), adequate liver function (SGPT = or < 3 times upper limit of normal and alkaline phosphatase = or < 2 times upper limit of normal, bilirubin = or <1.5 mg/dl), adequate renal function (BUN and creatinine = or <1.5 times upper limit of normal) and normal serum amylase and lipase prior to starting therapy. Elevated cholesterol and triglycerides are not a contraindication to study enrollment, but should be managed as clinically appropriate by the treating physician.
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values less than or equal to 2.5 times the upper limit of normal; patients with elevations of ALT or AST up to 10 times the upper limit of normal may be considered for participation if such elevations are thought to be due to liver involvement by malignancy; however, in these latter patients, if these values do not decrease to less than or equal to 2.5 times the upper limit of normal during induction chemotherapy, such patients will not be eligible for the transplant phase of the protocol, and will thus be taken off study
AST or ALT greater than 5 times upper limit of normal or greater than 250 U/l.
Transaminases > 3 times upper normal limit
Must have measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of ? 2 times the upper limit of each institution's normal value is required.
Total bilirubin < 2.5 times the upper limit of normal; in patients with liver metastasis, liver function tests should be < 5 times the upper limit of normal
Hepatic insufficiency (> 1.5 times the upper normal limit of transaminase levels)
Serum bilirubin levels =< 1.5 times the upper limit of the normal (ULN) range for the laboratory; higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis
Does the subject have an ALT < 3 times the upper limit of the laboratory reference range and total bilirubin < 1.5 mg/dL?
Subjects have adequate bone marrow, renal, and hepatic function as follows: Bone marrow: Absolute neutrophil count (ANC) >/= 1,500/mm3 Platelets >/= 100,000/mm3; Hemoglobin >/= 9.0 g/dL Renal function: Serum creatinine </= 1.5 times the upper limit of the institution's normal range Hepatic function: Bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) </= 1.5 times the upper limit of the institution's normal range. Subjects with liver metastasis may have an AST and ALT of </= 5.0 x the upper limit of normal.
INR and aPTT < 1.2 times upper limit of normal for age.
PT and aPTT each < 1.5 times the upper limit of normal.
Serum bilirubin greater than 1.25 times the upper limit of reference range (ULRR).
Elevated liver enzymes or bilirubin defined as 3 times the upper limits of normal
Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of > 2 times the upper limit of normal of each institution is required
Unexplained persistent elevation of transaminases (> 3 times upper limits of normal)
SUB-STUDY I: Liver transaminases > 5 times the upper limit of normal
SUB-STUDY II: Liver transaminases > 5 times the upper limit of normal
SUB-STUDY III: Liver transaminases > 5 times the upper limit of normal
Liver transaminases > 5 times the upper limit of normal
Pre-treatment laboratory tests for patients receiving [18F]FMISO must be performed within 21 days prior to the FMISO scan; these laboratory tests must be less than 4.0 times below or above the upper or lower limit range for the respective laboratory test for entry into the study (unless not clinically relevant); for those patients receiving Coumadin or another anticoagulant the upper limit for prothrombin time or partial thromboplastin time must not exceed 6 times the upper limit of the normal range
Prothrombin time less than 2.5 times below or above the upper or lower limit range; for those patients receiving Coumadin or another anticoagulant the upper limit for prothrombin time must not exceed 6 times the upper limit of the normal range
Hepatic enzymes 5 times greater than the upper limits of normal
PT and PTT ? 1.5 times the upper limit of normal
Patients should have adequate hepatic function with a total bilirubin within normal range and serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) < two times the upper limit of normal (ULN) for patients without liver metastasis and SGOT or SGPT < five times ULN for those with liver metastasis, and adequate renal function as defined by a serum creatinine within 1.5 times the upper limit of normal.
bilirubin ? 1.5 mg/dL; alanine aminotransferase (ALT), aspartate transaminase (AST) ? 2.5 times the upper limit of normal if no liver involvement or ? 5 times the upper limit of normal with liver involvement.
PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) =< 3 x ULN for subjects with Gilbert’s disease or with atazanavir- or indinavir-induced unconjugated hyperbilirubinemia without aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation and must have a total bilirubin less than 3.0 mg/dL, within 2 weeks prior to enrollment
Hepatic: bilirubin <1.5 X Upper Limit of Normal (ULN); alkaline phosphatase (ALP), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 X ULN
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Adequate liver function with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than 3 X upper limit of normal and total bilirubin less than 2 mg/dL within 7 days prior to first dose of study agent
ELIGIBILITY CRITERIA - PHASE II (ARM D): Adequate liver function with AST/ALT less than 3 X upper limit of normal and total bilirubin less than 2 mg/dL within 7 days prior to first dose of study agent
Obtained =< 21 days prior to registration: Total Bilirubin =< 1.5 x upper limit of normal (ULN)\r\n* NOTE: For bilirubin elevation 1 to 1.5 x ULN, alanine aminotransferase (ALT) above 1.5 x ULN (upper limit of normal) is not permitted\r\n* NOTE: For bilirubin elevation 1 to 1.5 x ULN, aspartate aminotransferase (AST) above 1.5 x ULN (upper limit of normal) is not permitted
Liver function tests above the following limits at Screening: total bilirubin >1.5 x upper limit of normal (ULN) unless related to Gilbert's syndrome or hemolysis; aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 x ULN; for subjects with liver involvement, AST and/or ALT >5 x ULN;
Adequate liver function as demonstrated by: Total bilirubin of < upper limit of normal (ULN), Aspartate transaminase (AST) and alanine aminotransferase (ALT) ?1.5 × ULN, Alkaline phosphatase (ALP) ?2.5x ULN or <5x ULN if bone metastases are present, Normal serum albumin
Meets laboratory criteria for the following parameters: ANC, platelets, hemoglobin, total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, BUN and creatinine.
Clinically-significant inadequate hematological, hepatic and renal function, defined as: Neutrophil count < 1.5 x 10 9/L and platelet count < 100 x 10^9/L; bilirubin > 1.5 x upper limit of normal (ULN); aspartate transaminase (AST) and/or alanine aminotransferase (ALT) > 2.5 x ULN or > 5 x ULN if patient has documented liver metastases; and serum creatinine > 1.5 x ULN
Hepatic status: Serum total bilirubin ? 1 x upper limit of normal (ULN; in the case of known Gilbert's syndrome, a higher serum total bilirubin [< 1.5 x ULN] is allowed), aspartate aminotransferase and alanine aminotransferase ? 1.5 x ULN, and alkaline phosphatase ? 1.5 x ULN;
Adequate hepatic function, with total bilirubin ?1.5 x upper limit of normal (ULN) (except for Gilbert Syndrome: total bilirubin < 3.0 x ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?3.0 x ULN.
Hepatic: Total bilirubin < 3.0 x the upper limit of normal (ULN) for age (patients who have been diagnosed with Gilbert's Disease are allowed to exceed this limit) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5.0 x ULN for age.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN) for patients receiving MAC or ALT and AST =< 10 x ULN for patients receiving RIC, RIC-MMF, or IOC; patients who are above these bilirubin, ALT, or AST thresholds may be eligible for the RIC, RIC-MMF or IOC arms if evaluated by a hepatologist who deems the liver function test abnormalities to be potentially reversible with bone marrow transplant
ALT (alanine aminotransferase; SGPT), AST (aspartate aminotransferase; SGPT), alkaline phosphatase (ALP) >2.5 upper limit of normal (ULN), unless attributed to GVHD.
Creatinine > 1.5 x institutional upper limit of normal (ULN); total bilirubin > 1.5 x ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3.0 x ULN.
Adequate bone marrow and major organ function to undergo a PBSC transplant determined within 30-60 days prior to enrollment using standard phase 1 criteria for organ function defined as:\r\n* Absolute neutrophil count (ANC) >= 1.5 x 10^9 cells/L\r\n* Platelets >= 75 x 10^9/L\r\n* Hemoglobin >= 8 g/dL\r\n* Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)\r\n* Total bilirubin =< 2 x ULN (except patients with documented Gilbert’s syndrome)\r\n* Creatinine < 2 mg/dl (or a glomerular filtration rate > 60)\r\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Severely impaired renal or hepatic function (eg, serum creatinine level > 2 mg/dL [176.8 ?mol/L], blood urea nitrogen level >50 mg/dL [17.9 mmol/L], serum aspartate aminotransferase [AST] level >3 times the upper limit of normal [ULN], or serum alanine aminotransferase [ALT] level > 3 times ULN).
Adequate hepatic function as evidenced by: serum total bilirubin ?1.5 × ULN unless considered due to Gilbert's disease, a gene mutation in UGT1A1 (only for patients who will be receiving AG-221), or leukemic involvement following approval by the study Sponsor; aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ?3.0 × ULN, unless considered due to leukemic involvement following approval by the study Sponsor
Normal organ and marrow function: Leukocytes ? 3000/?L, Absolute neutrophil count ? 1500/?L, Platelets ? 100,000/?L, Total bilirubin within normal institutional limits, unless patient has Gilbert's disease, for which bilirubin must be ? 2.0 x ULN, AST(SGOT)/ALT (SGPT) ? 1.5 x institutional ULN, creatinine < 1.5 x institutional ULN
Adequate renal and liver function as indicated by: i. Creatinine ? 1.5 x upper-normal limit (ULN) ii. Total bilirubin ? 1.5 x upper-normal limit (ULN) iii. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN iv. Alkaline phosphatase ? 2.5 x ULN
Clinically significant kidney (e.g. glomerular filtration rate [GFR] =< 45ml/minute or creatinine of >= 2 mg/dl) or liver dysfunction (e.g. aspartate aminotransferase [AST]/alanine aminotransferase (ALT) and/or bilirubin >= 2 times upper limit of normal [ULN]) at the time of enrollment that may prevent from safely using chemotherapy; such patients may be allowed to receive low-intensity chemotherapy; patients with elevated bilirubin secondary to Gilbert syndrome will not be excluded; discussion with the principal investigator is encouraged if further clarification is required
Liver function tests meeting one of the following criteria:\r\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) with alkaline phosphatase < 2.5 x ULN OR\r\n* AST and ALT < 1.5 x ULN, with alkaline phosphatase > 2.5 x ULN
have adequate hepatic function, defined as having a serum total bilirubin concentration ?1.5mg/d, or ?2 x the upper limit of normal (ULN) if associated with hepatobiliary metastases or Gilbert syndrome, and having serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations ?2.5 × ULN, or ?5 x ULN for patients with known hepatic metastases;
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x ULN and total bilirubin < 2.0 mg/dL unless due to malignancy or Gilbert’s syndrome in the opinion of the PI or designee
Have serum aspartate aminotransferase (AST) >5 times upper limit of normal (ULN) at screening, or serum alanine aminotransferase (ALT) >5 times ULN at screening, or total bilirubin >=3.0 x ULN at screening (except for documented Gilbert's syndrome), as analyzed by local or central lab.
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x the institutional upper limit of normal (unless demonstrated Hodgkin lymphoma involvement of the liver); estimated creatinine clearance >= 30 ml/min (Cockcroft-Gault) and/or 24 urine analysis as needed
Bilirubin =< 1.5 mg/dl (unless Gilbert's syndrome), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 200 IU/ml for adults; conjugated (direct) bilirubin < 2 x upper limit of normal
Liver function (total bilirubin <2mg/dL and aspartate aminotransferase and/or alanine aminotransferase <3 × upper limit of normal (ULN) or <5 × ULN if related to leukemic involvement)
Liver function (total bilirubin <2mg/dL and aspartate aminotransferase and/or alanine aminotransferase <3 × upper limit of normal (ULN) or <5 × ULN if related to leukemic involvement)
Adequate organ function as indicated by the following laboratory values. All laboratory tests must be obtained within 7 days prior to the first dose of ARQ 751: a. Hematological i. Absolute neutrophil count (ANC) ? 1.5 x 109/L ii. Platelet count (Plt) ? 100 x 109/L iii. Hemoglobin (Hb) ? 9 g/dL iv. International normalized ratio (INR) 0.8 to upper limit of normal (ULN) or ? 3 for subjects receiving anticoagulant therapy such as Coumadin or heparin b. Renal i. Serum creatinine ? 1.5 x ULN or calculated creatinine clearance ? 60 mL/min/1.73 m2 for subjects with serum creatinine levels > 1.5 x institutional ULN c. Hepatic i. Total bilirubin ? 1.5 x ULN ii. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 x ULN or ? 5 x ULN for subjects with known liver metastases d. Metabolic i. Glycated hemoglobin (HbA1c) ? 8%
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (unless demonstrated Hodgkin lymphoma involvement of the liver); estimated creatinine clearance >= 30 ml/min (Cockcroft-Gault) and/or 24 urine analysis as needed
Adequate organ function =< 21 days prior to registration:\r\n* Aspartate transaminase (AST) level =< 2.5 x upper limit of normal (ULN) and alanine transaminase (ALT) =< 3 x upper limit of normal (ULN)\r\n* Total bilirubin level of =< 1.5 x ULN\r\n* Creatinine level =< 1.2 x ULN or creatinine clearance > 60 mL/min/1.73 m^2 for patients with creatinine levels above or below the institutional normal\r\n* Hemoglobin (Hgb) >= 9 g/dl without transfusion or epoetin dependency (=< 7 days prior to assessment)\r\n* Absolute neutrophil count >= 1.5 x 10^9/L\r\n* Platelets >= 100 x 10^9/L\r\n* Albumin >= 2.5 g/dl
Patient must meet the following laboratory values at the screening visit: Absolute Neutrophil Count ?1.5 x 109/L. Platelets ?75 x 109/L. Hemoglobin (Hgb) ?9 g/dL. Serum creatinine <1.5 mg/dL. Total bilirubin ?1.5 x upper limit of normal (ULN) (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). Aspartate transaminase (AST) ? 3.0 x ULN, except for patients with liver metastasis, who may only be included if AST ?5.0 x ULN. Alanine transaminase (ALT) ? 3.0 x ULN, except for patients with liver metastasis or tumor infiltration, who may only be included if ALT ?5.0 x ULN. Prothrombin time (PT)/International normalized ratio (INR) and Partial thromboplastin time (PTT) ?1.5xULN. Note: patients receiving therapeutic anticoagulation agents prior screening are permitted. Albumin 2.5 g/dL.
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 × ULN (>= 5 × ULN for patients with concurrent liver metastasis); OR impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices; OR acute viral or active autoimmune, alcoholic, or other types of hepatitis
Hepatic: Serum/plasma total bilirubin ?1.5 x upper limit of normal (ULN) with the exception of <2.9 mg/dL for patients with Gilbert's disease, ALT (SGPT) and AST (SGOT) ?2.5 x ULN.
Laboratory values: Screening serum creatinine >1.5×upper limit of normal (ULN), alanine aminotransferase (ALT) >3×ULN or >5×ULN if liver metastases are present, total bilirubin >2×ULN, absolute neutrophil count (ANC) <1,500/mm3, platelet concentration <100,000/mm3, hemoglobin <9 g/dL, albumin <2 gm/dL.
Adequate hepatic function as defined by the following criteria:\r\n* Total serum bilirubin =< 1.5 x upper normal limit (ULN), unless due to Gilbert’s syndrome\r\n* Alanine aminotransferase (ALT) =< 2.5 x ULN\r\n* Aspartate aminotransferase (AST) =< 2.5 x ULN
Patients must have adequate hepatic function as evidenced by total serum bilirubin ? 1.5 x the upper limit of normal (ULN) and a prothrombin time (PT) within 2 seconds of the upper normal limit. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) must be ? 2.5 x ULN.
Severe major organ toxicity; renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 1 or less (per National Cancer Institute [NCI] Common Toxicity Criteria [CTC] version 3 criteria) with the following exceptions:\r\n* Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase should be =< 5 x upper limit of normal (ULN)\r\n* Serum bilirubin =< 3 x ULN and nausea and vomiting should be =< grade 2\r\n* Patients with myelosuppression are not excluded if absolute neutrophil count (ANC) >= 500/uL
Patients with organ dysfunction will not be excluded from the study; for patients with evidence of organ dysfunction (creatinine >= 1.5, cardiac ejection fraction =< 50%, total bilirubin >=2 and aspartate aminotransferase [AST]/alanine aminotransferase [ALT] >= 3 times upper limit of normal [ULN]), dose adjustments/omissions will be made
Adequate liver function (total bilirubin ?1.5 X ULN (or ?3 X ULN in patients with documented Gilbert's syndrome or for patients with hyperbilirubinemia considered due to myeloid disease), alanine aminotransferase [ALT] and aspartate aminotransferase [AST] ?3 X ULN (or ?5 X ULN for patients with liver involvement of their myeloid disease)
Adequate baseline laboratory data: hemoglobin >9 g/dL, absolute neutrophil count (ANC) ?1,000/µL, CD4+ T-cells ?200/µL, platelets ?50,000/µL, bilirubin ?1.5 X upper limit of normal (ULN) or ?3 X ULN for patients with Gilbert's disease, serum creatinine ?1.5 X ULN, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ?3 X ULN.
Have adequate organ function, confirmed by the following laboratory values obtained ? 3 days prior to the first treatment: absolute neutrophil count ? 1.5 × 10^9/L; hemoglobin ? 9 g/dL; platelets ? 100 × 10^9/L; aspartate transaminase and alanine transaminase ? 2.5 × upper limit of normal (ULN); serum total bilirubin ? 2.0 × ULN; serum creatinine ? 1.5 × ULN, or estimated or measured creatinine clearance ? 60 mL/min; prothrombin time, activated partial thromboplastin time ? 1.5 × ULN if not on anticoagulation therapy
Patients with serum aspartate aminotransferase, alanine aminotransferase > 2.5 X the upper limit of normal (ULN) and bilirubin >1.5 ULN
Laboratory values: Screening serum creatinine > upper limits of normal (ULN); total bilirubin > ULN: alanine aminotransferase (ALT) and AST >/= 2.5 ULN or >/= 5.0 x ULN if liver metastases are present; absolute neutrophil count < 1,500/mm3, platelet concentration < 100,00/mm3, hematocrit level < 27% for females or < 30% for males, or coagulation tests (prothrombin time [PT], partial thromboplastin time [PTT], International Normalized Ratio [INR]) > 1.5 x ULN unless on therapeutic doses of warfarin.
Adequate hepatocellular function: aspartate aminotransferase (AST) and alanine transaminase (ALT) ? 3x upper limit of normal within institutional limits; bilirubin ? 1.5 mg/dl
Hepatic function: total bilirubin ? 1.5 x ULN (Common Terminology Criteria for AEs [CTCAE] v4.0 grade 1) except patients with Gilbert's disease (up to 5.0 mg/dL). Aspartate aminotransferase (AST) and alkaline phosphatase ? 2.5 x ULN.
Subjects with adequate organ system functions as defined follows: Absolute neutrophil count (ANC) >=1.0 X 10^9/L; Hemoglobin >=8.0 g/dL; Platelets>= 50 X 10^9/L; Total bilirubin <=1.5X Upper limit of normal (ULN). Isolated bilirubin >=1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent); Alanine aminotransferase (ALT) <=2.5X ULN; Estimated glomerular filtration rate (eGFR) >=30 milliliter per minute per 1.73 meter square (mL/min/m^2); Spot urine (albumin/creatinine ratios [spot urine]) < 500 milligram per gram (mg/g) (56 mg per millimoles [mg/mmol]); Left ventricular ejection fraction (LVEF) >= 45 percent.
109 Laboratory parameters (completed within 14 days prior to enrollment): Hematology: Absolute neutrophil count (ANC) ? 1.0 x 10^9/L, Platelets ? 75 x 10^9/L. Chemistry: Creatinine clearance ? 50 mL/min (calculated using Cockcroft Gault equation). Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3X upper limit of normal (ULN), Total bilirubin (TBL) < 2x ULN (unless Gilbert's disease or if liver involvement with lymphoma)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level > 3 times the upper limit of normal (x ULN); patients with values > 3 x ULN and < 5 x ULN are eligible if the value is acute and directly related to the infectious process being treated
Must have adequate organ function as defined by the following values: white blood cells >3 x 10^9/liter(L); absolute neutrophil count (ANC) >= 1.5 x 10^9/L; hemoglobin >= 9 grams per decilitre (g/dL) subjects that required transfusion or growth factor need to demonstrate stable hemoglobin for 7 days of 9 g/dL; platelets >=100 x 10^9/L; prothrombin time (PT)/International normalized ration (INR) and partial thromboplastin time (PTT) <= 1.5 x upper limit of normal (ULN); albumin >=2.5 g/dL; total bilirubin <=1.5 x ULN; aspartate transaminase (AST) <=2.5 x ULN; alanine transaminase (ALT) <=2.5 x ULN OR <5 x ULN; creatinine <=1.5 x ULN is acceptable for subjects with documented liver metastases/tumor infiltration; creatinine clearance >= 50 mL/min; ejection fraction>= lower limit of normal (LLN) by echocardiogram or multigated acquisition (MUGA) and minimum of 50% left ventricular ejection fraction (LVEF); testosterone <=50 nanograms per deciliter (ng/dL)
Subject has a total bilirubin ? 1.5 x upper limit of normal (ULN), albumin ? 2.5 g/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN
Adequate bone marrow function (absolute neutrophil count > 1,500/mm3 and platelet count of > 100,000/mm3), adequate liver function [ALT and AST <3 x upper limit normal (ULN), alkaline phosphatase <2 x ULN, and total bilirubin <1.5 mg/dL], & adequate renal function (BUN and creatinine <1.5 x ULN)
Patients with severe hepatic disease (direct bilirubin greater than 3 mg/dl or aspartate aminotransferase [AST] greater than 500 IU/L)
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal; NOTE: adult values will be used for calculating hepatic toxicity and determining eligibility, as is standard on POB phase I trials
Patient with severe hepatic disease (direct bilirubin greater than 3 mg/dl or aspartate aminotransferase [AST] greater than 500 IU/L)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x institutional ULN; note: patients who have both bilirubin > ULN and AST/ALT > ULN are not eligible (unless they have Gilbert's syndrome and elevations of indirect bilirubin)
Subject has adequate liver function, which is defined as: • Total bilirubin is ? 2 mg/dL unless the increase in bilirubin is attributable to Gilbert's Syndrome • AST is ? 3.0 x upper normal limit (ULN) for age. For the purpose of this study, the ULN for AST is 50 U/L. • ALT is ? 3.0 x upper normal limit (ULN) for age. For the purpose of this study, the ULN for ALT is 45 U/L.
Subjects must have adequate hepatic function as evidenced by: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ?3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ?1.5 x upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic disease
Patient must have adequate hepatic function as evidenced by: Serum total bilirubin ?1.5 × upper limit of normal (ULN), unless considered due to Gilbert's disease or disease involvement; Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ?2.5 × ULN. For patients with bone metastases and/or suspected disease-related liver or biliary involvement, AST, ALT and ALP must be ?5 × ULN
Hepatic: alanine aminotransferase (ALT), and aspartate aminotransferase (AST) > 2.5 x ULN, total serum bilirubin > 1.5 x ULN (patients with Gilbert's Disease may be included if their total bilirubin is ?3.0 mg/dL)
Inadequate organ function immediate prior to randomization including: Hemoglobin <10g/dL (100g/L); ANC < 2000/mm³ (< 2.0 x 109/L); Platelets <100,000/mm³ (< 100 x 109/L); AST or ALT >1.5 x upper limit of normal (ULN); alkaline phosphatase > 2.5 x ULN, total serum bilirubin > 1.25 x ULN; serum creatinine >1.25 x ULN or estimated creatinine clearance < 60 mL/min as calculated using the method standard for the institution; severe and relevant co-morbidity that would interact with the participation in the study
Hepatic: alanine aminotransferase (ALT), and aspartate aminotransferase (AST) > 2.5 x ULN, total serum bilirubin > 1.5 x ULN (patients with Gilbert's Disease may be included if their total bilirubin is ? 3.0 mg/dL).
Subject has total bilirubin (TBL) ? 1.5 x the upper limit of normal (ULN) (except subjects with documented Gilbert's disease), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? 2.5 x the ULN .
Hepatic: alanine aminotransferase (ALT), and aspartate aminotransferase (AST) > 2.5 x Upper Limit of Normal (ULN), total serum bilirubin > 1.5 x ULN (patients with Gilbert's Disease may be included if their total bilirubin is ?3.0 mg/dL)
Screening values of serum alanine aminotransferase (ALT) and/or aspartate transaminase (AST) ? 2.5 x upper limit of normal (ULN), total bilirubin ? 1.5 x ULN, creatinine ? 2.0 x ULN.
Hepatic: Aspartate aminotransferase/Alanine aminotransferase <3X upper limit of normal (ULN); Total bilirubin <2X ULN (unless Gilbert's Disease or if liver involvement with lymphoma)
Screening chemistry values of the following: alanine aminotransferase (ALT) and aspartate transaminase (AST) ? 3.0 × upper limit of the normal reference range (ULN), total bilirubin ? 2 × ULN, creatinine ? 1.5 × ULN, fasting blood glucose < 140 mg/dL, hemoglobin A1C ? ULN, albumin ? 2.8 g/dL.
Hepatic function: serum albumin >3.0 g/dL; aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) <3x the upper limits of normal (ULN); alkaline phosphatase <2x the ULN
Total bilirubin =< 1.5 x upper limit of normal (ULN); patients with known history of Gilbert syndrome and total bilirubin < 2 x ULN and normal aspartate aminotransferase (AST)/alanine aminotransferase (ALT) are eligible, obtained =< 7 days prior to registration
Hepatic: total bilirubin ? 2.5 mg/dL, and alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) < 5 x upper limit of (ULN) (unless disease related)
Adequate bone marrow, hepatic, renal and coagulation function as defined by the following: Absolute neutrophil count ?1.5 x 10^9/L, Hemoglobin ?9.0 g/dL (90 g/L), Platelets ?100 x 10^9/L, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 x upper limit of normal (ULN) (if no hepatic metastases). If hepatic tumor involvement, AST and ALT ?5 x ULN, Bilirubin ?1.5 x ULN, Prothrombin time (PT) / international normalized ratio (INR) ?1.5 x ULN, Calculated creatinine clearance >50 mL/min using the Cockcroft and Gault equation
Absolute neutrophil count (ANC) >=1.5 X 10^9/liter (L), Hemoglobin >=9 grams (g)/deciliter (dL) (subjects that required transfusion or growth factor need to demonstrate stable hemoglobin for 7 days of 9 g/dL), Platelets >=100 X 10^9/L, prothrombin time (PT)/ international normalized ratio (INR) and partial thromboplastin time (PTT) - <=1.5 X upper limit of normal (ULN); Hepatic - Albumin >=2.5 g/dL, Total bilirubin <=1.5 X ULN (isolated bilirubin >1.5 X ULN is acceptable if bilirubin is fractionated and direct bilirubin <35% or subject has a diagnosis of Gilbert's syndrome), Alanine aminotransferase (ALT) <=2.5 x ULN OR <5 x ULN is acceptable for subjects with documented liver metastases/tumor infiltration; Renal - Creatinine <=1.5 X ULN OR Creatinine clearance [either directly measured or calculated by Cockcroft-Gault formula] >=40 milliliter (mL)/minute (min); Cardiac - Ejection fraction >=50% by echocardiogram or multigated acquisition scan (MUGA), Troponin (T) <=ULN, Potassium >=Lower limit of normal (LLN) and <=ULN, Magnesium >=LLN
Hepatic: Serum total bilirubin <=1.5 x upper limit of normal (ULN) (Patients with Gilbert's Disease may be included if their total bilirubin is <= 3.0 mg/dL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <= 2.5 x ULN. If the patient has known liver metastases, an ALT and/or AST <= 5 x ULN are allowed.
Has adequate hepatic function defined as total bilirubin ?1.5 mg/dL, unless associated with hepatobiliary metastases or Gilbert syndrome, then total bilirubin or ? 2 ULN. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × upper limit of normal (ULN) or ? 5 x ULN for subjects with known hepatic metastases.
Major Inclusion Criteria:\n\n          1. Signed written informed consent must be obtained and documented according to the\n             International Conference on Harmonisation (ICH) and be in accordance with local\n             regulatory requirements\n\n          2. A histologically confirmed hematologic malignancy that is advanced, relapsed, or\n             refractory to standard, currently available anti-cancer treatment options\n\n          3. ? 18 years of age\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status of ? 1 at dose escalation\n             phase and of ? 2 at dose expansion phase\n\n          5. Male or female patients of child-producing potential must agree to use contraception\n             or avoidance of pregnancy measures during the study and for 30 days after their last\n             dose\n\n          6. Females of childbearing potential must have a negative serum pregnancy test\n\n          7. Aspartate transaminase (AST) ? 2.5 x upper limit of normal (ULN) and alanine\n             transaminase (ALT) ? 2.5 × upper limit of normal (ULN). Patients whose disease\n             involves the liver and who have laboratory values of AST ? 3.5 ULN, AST ? 3.5 ULN, and\n             albumin ? 35g/L may be enrolled if agreed upon by the Principal Investigator and\n             Medical Monitor for the Sponsor\n\n          8. Total bilirubin < 1.5 x ULN, except for cases in which elevation of total bilirubin is\n             due to elevated levels of unconjugated bilirubin consistent with a diagnosis of\n             Gilbert's Syndrome\n\n          9. Life expectancy ? 3 months
Adequate bone marrow, liver, and renal function defined as: 1) Absolute neutrophil count (ANC) greater than equal to (>=) 1.5* 10^9cells/litre (L); 2) Platelets >=75 x 109cells/L without transfusion support within 7 days prior to test; 3) Hemoglobin >= 8 gram/deciliter (g/dL) without transfusion support within 7 days prior to test 4) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than equal to (<=) 2.5 * upper limit of normal (ULN) 5) Total bilirubin less than (<) 2 milligram/deciliter (mg/dL) 6) Creatinine determined by serum creatinine levels <=1.5 * ULN or a calculated creatinine clearance of >= 50 mL/min/1.73 m^2
Inadequate liver function: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 3 liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] >5× upper limit of normal [ULN] for >2 weeks; bilirubin >3× ULN) unless due to underlying disease
The following criteria for evidence of adequate hepatic function performed within 4 weeks prior to study entry must be met: total bilirubin must be less than or equal to upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation greater than ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and alkaline phosphatase must be must be less than or equal to 1.5 x ULN for the lab; and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to 1.5 x ULN for the lab.
Demonstrate adequate organ function as defined below, all screening labs should be performed within 28 days of treatment initiation\r\n* Absolute neutrophil count (ANC) >= 1,000/mcL\r\n* Platelets >= 75,000/mcL\r\n* Hemoglobin >= 9 g/dL\r\n* Serum creatinine =< 2 mg/dl OR creatinine clearance (if creatinine [Cr] > 2 mg/dL) >= 60 mL/min; creatinine clearance should be calculated per institutional standard\r\n* Serum total bilirubin =< 1.5 X upper limit of normal (ULN)\r\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X ULN\r\n* International normalized ratio (INR) =< 1.5 X ULN; activated partial thromboplastin time (aPTT) >= 1.5 X ULN; if on anticoagulant therapy (prothrombin time [PT] or PTT should be therapeutic)
Adequate organ function as determined by: i. Absolute neutrophil count ? 1.5 x 109/L (1,500/mm3) ii.Platelet count ? 100 x 109/L (100,000/mm3) iii.Hemoglobin ? 9.0 g/dL within first 2 weeks prior to first dose of investigational product iv.Calculated creatinine clearance* (CrCl) or 24 hour urine CrCl > 50 mL/min v.Total bilirubin ? 1.5× ULN; for subjects with documented/suspected Gilbert's disease, bilirubin ? 3× ULN vi.Aspartate transaminase (AST) and alanine transaminase (ALT) ? 2.5× ULN vii.Serum Electrolytes within normal limits
Creatinine > 1.5 x institutional upper limit of normal (ULN); total bilirubin > 1.5 x ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN unless disease related.
Total bilirubin level ?1.5 times institutional upper limit of normal (ULN), alanine aminotransferase or aspartate aminotransferase ?2 x ULN
Creatinine > 1.5 x institutional upper limit of normal (ULN); total bilirubin > 1.5 x ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3.0 x ULN unless disease related.
Subject's total bilirubin is ? 1.5 x upper limit of normal (ULN) (except for subjects with documented Gilbert's disease) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is ? 2.5x upper limit of normal (ULN) at Screening.
The following criteria for evidence of adequate hepatic function performed within 4 weeks prior to study entry must be met: Total bilirubin must be less than or equal to 1.5 x upper limit of normal (ULN); aspartate aminotransferase (AST) and ALT must be less than or equal to 2.5 x ULN for the lab or less than or equal to 5 x ULN if liver metastasis;
Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Alkaline phosphatase (ALP) ?3.0 × ULN (Upper limit of normal), unless considered due to leukemic organ involvement.
Acceptable hematology and serum biochemistry screening values: White Blood Cell Count (WBC) >= 1500/mm3; Absolute Neutrophil Count (ANC) >= 1,000/mm3; Platelet (PLT) count >= 75,000/mm3; Hemoglobin (HGB) >= 8 g/dl; Total bilirubin level <= 1.5 x institutional upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 x ULN; Creatinine <= 1.5 x ULN; Albumin > 25 g/L
Patients must have WBC >/= 3.5 x 10^9/L, ANC >/= 1.5 x 10^9/L, platelets >/= 100 x 10^9/L, Hb >/= 9.0 g/dL); total bilirubin </= 1.5 x ULN, AST and ALT </= 1.5 x the upper limit of normal; serum potassium of >/= 3.5 mEq/L, serum albumin of >/= 3.0 g/dL, serum creatinine </= 1.5 x ULN
Hepatic: Serum total bilirubin ?1.5 x upper limit of normal (ULN) with the exception of <2.9 mg/dL for patients with Gilbert's disease, alanine aminotransferase (ALT/SGPT) and aspartate aminotransferase (AST/SGOT) ?2.5 x ULN.
Patients must have the following clinical laboratory values unless considered due to leukemic organ involvement: 1. Serum creatinine </= 2.0 mg/dl. 2. Total bilirubin </= 1.5x the upper limit of normal unless considered due to Gilbert's syndrome. 3. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) </= 3x the upper limit of normal.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?3 × the upper limit of normal (ULN) and total bilirubin ?1.5 × ULN. If the total bilirubin is elevated between 1.5 x and 3 x ULN, patients with a direct bilirubin ? 1.5 X ULN are eligible during the Phase II portion.
Adequate liver function as evidenced by bilirubin less than 1.5 times the upper limits of normal (ULN) and alkaline phosphatase (AP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than 3 x ULN.
Aspartate aminotransferase and alanine aminotransferase values 3.0 x ULN (or 5x ULN in the case of patients with MF accompanied by hepatic extramedullary hematopoiesis, as manifested by any degree of hepatomegaly).
Subjects must have adequate liver function assessed by: total bilirubin <= 1.0 x upper limit of normal (ULN), aspartate aminotransferase (ALT) <= 3.0 x ULN (CTCAE Grade <=1) or, if receiving BAY1143269 in combination with IV docetaxel, AST and ALT <=1.5 x ULN if concomitant with alkaline phosphatase increase >2.5 x ULN
Hepatic function: Total bilirubin < 1.5 × upper limit of normal (ULN) (except in the case of subjects with known Gilbert's disease: < 5 × ULN) and transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) < 3 × ULN based on age- and institution specific laboratory-specific normal ranges
Serum total Bilirubin ? 1.5 x ULN (upper limit of normal) or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 2.5 x ULN
Adequate baseline organ function defined by the criteria below: total bilirubin =< 1.5x the upper limit of normal (ULN) except for Gilbert's syndrome or cases clearly not indicative of inadequate liver function (i.e. elevation of indirect [haemolytic] bilirubin in the absence of alanine aminotransferase [ALT] abnormality); ALT =< 2.5xULN; creatinine =< 2.5xULN
Adequate bone marrow function [absolute neutrophil count (ANC) > 1,500/mm3 & platelet count of > 100,000/mm3], adequate liver function [alanine aminotransferase (ALT) & aspartate aminotransferase (AST) <3 x upper limit normal (ULN), alkaline phosphatase <2 x ULN, & total bilirubin <1.5 mg/dL], & adequate renal function (BUN & creatinine <1.5 x ULN)
Elevated serum aspartate aminotransferase, alanine aminotransferase, or bilirubin (unless there is medical justification for bilirubin elevation, and aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase are normal)
Bilirubin =< 1.5 mg/dL AND alkaline phosphatase =< 3 x the upper limit of normal (ULN) for the reference lab (=< 5x the ULN for patients with known hepatic metastases and no limit for patients with known bone metastases) AND aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3x the ULN ( =< 5x the ULN for patients with known hepatic metastases)
Liver dysfunction: aspartate transaminase, alanine aminotransferase increase ?2-fold above the upper-limit of local lab normal ranges.
Have adequate marrow and organ function as defined in Table 2. Table 2 Laboratory Values SYSTEM LABORATORY VALUES Hematologic ANC ?1.5 x 109/L Hemoglobin ?9 g/dL (after transfusion if needed) Platelets ?100 x 109/L Hepatic Albumin ?2.5 g/dL Serum bilirubin ?1.5 x ULN unless due to Gilbert's syndrome AST and ALT ?3 x ULN Renal Calculated creatinine clearance* ? 40 mL/min Serum Creatinine ?1.5 mg/dL or 132.6?mol/L *Calculated by the Cockcroft-Gault Equation (Refer to protocol for details) Abbreviations: ANC, absolute neutrophil count; ULN, upper limit of normal; AST, aspartate aminotransferase; ALT, alanine aminotransferase
Participants with normal major organ functions as defined by hemoglobin (HgB) >= 8.5 gram/decilitre (dL), absolute neutrophil count (ANC) >= 1000/microliter (mcL), platelet >= 60,000/micL, aspartate aminotransferase/alanine transaminase (AST/ALT) <= 3 x Upper Limit of Normal (ULN), total Bilirubin <= 2 x ULN, creatinine <= 2 x ULN.
Participants with normal hepatic function: Total bilirubin and alanine aminotransferase (ALT) must be ? upper limit of the normal range (ULN).
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) <=2.5*ULN • For participants to be treated with MLN4924 + docetaxel in Part B, AST and ALT must be <=1.5*ULN, and total bilirubin should be within the normal range.
Adequate baseline organ function defined as: absolute neutrophil count >= 1.2 x 10^9/Liter (L); hemoglobin>=9 gram per deciliter (g/dL); platelets >= 75 x 10^9/L; prothrombin time /international normalized ratio and partial thromboplastin time =<1.3 x ULN; serum bilirubin=<1.5 times upper limit of normal (ULN); aspartate aminotransferase and alanine aminotransferase =<2.5 times ULN; serum creatinine=<1.5 mg/dL or calculate creatinine clearance >= 50 milliliter per minute; Left ventricular ejection fraction>= lower limit of normal by echocardiography.
Laboratory values: Screening serum creatinine >1.5 x upper limit of normal (ULN), alanine aminotransferase (ALT) >3×ULN or >5×ULN if liver metastases are present, total bilirubin >2×ULN, absolute neutrophil count (ANC) <1,500/mm3, platelet concentration <100,000/mm3, hemoglobin <9g/dL.
Adequate hepatic parameters as defined by total bilirubin ? 1.5 x upper limit of normal (ULN) and aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ? 3 x ULN
Total bilirubin level ?1.5 times institutional upper limit of normal (ULN), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ?2.0 x ULN except in subjects with known hepatic metastasis, where AST or ALT can be ?5.0 x ULN.
Have adequate baseline organ function defined by the following criteria: Total bilirubin <=1.5 x upper limit of normal (ULN) except for Gilbert's syndrome, or other conditions that are not indicative of inadequate liver function (i.e. elevation of indirect bilirubin (haemolytic) in the absence of alanine aminotransferase [ALT] abnormality). ALT <=3 x ULN. Serum Creatinine <=2.5 x ULN.
Must have adequate organ function as defined by the following baseline values: Absolute neutrophil count >=1.5 x 10^9/Liter, Hemoglobin >=9 gram (g)/decilitre(dL), Platelets >=100 x 10^9/L, Partial thromboplastin time (PTT) <=1.25 x upper limit of normal (ULN), Albumin >=2.5 g/dL, Serum total bilirubin <=1.25 times ULN (for Arm B: <=ULN ), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) <=2.5 times ULN (for Arm B: <=1.5 times ULN), Serum Creatinine <=1.5 x ULN, Or Measured or Calculated Creatinine Clearance >=45 mL/min (Arm A or B), >=65 mL/min (Arm C), Left ventricular ejection fraction >=50% by ECHO.
Adequate baseline organ function as defined by: absolute neutrophil count (ANC) >= 1.2 × 109/L; Hemoglobin >= 9 g/dL; Platelet count >= 100 x 109/L; prothrombin time (PT) / international normalized ratio (INR) and partial thromboplastin time (PTT) <= 1.5 x upper limit of normal (ULN); Albumin >= 2.5 g/dL; Total bilirubin <= 1.5 x ULN; aspartate aminotransferase (AST) and alanine transaminase (ALT) <= 2.0 x ULN; Creatinine <=1.5 mg/mL; Left Ventricular Ejection fraction (LVEF) >= lower limit of normal (LLN) by ECHO
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBILI) each < 3 x the upper limit of normal (ULN); however, ALT, AST, and TBILI each ? 5 x ULN is acceptable if the elevation is considered by the investigator to be due to PTLD involvement of the liver
Elevated liver function tests (LFTs): Serum bilirubin >upper limit of normal (ULN), alanine (ALT) or aspartate (AST) aminotransferase > 1.5 ULN concomitant with alkaline phosphatase > 2.5 ULN
Documentation of inclusion criteria adequate organ function as evidenced by the following peripheral blood counts or serum chemistry values: hemoglobin 9 gram per deciliters (g/dL), absolute neutrophil count (ANC) 1,500/L, platelet count 100,000/L, serum creatinine 1.5*the upper limit of normal (ULN), creatine phosphokinase (CPK) 2.5*ULN and adequate hepatic function as evidenced by the following serum chemistry values: total bilirubin, ULN. If total bilirubin is greater than (>) ULN, measure indirect bilirubin to evaluate for Gilbert's syndrome (if direct bilirubin is within normal range, participant may be eligible) ALP <= 2.5*ULN; Trabectedin: if the ALP is >2.5*ULN, then an ALP liver fraction or 5-nucleotidase must be obtained and ULN, AST and ALT 2.5 ULN will be reviewed by the Sponsor before enrollment in the OEP may occur
Patient has adequate hepatic function (serum bilirubin values <2.0 mg/dL and ALT and/or AST values <3 × the upper limit of normal ULN).
Patients enrolled with hepatic dysfunction must have laboratory test results for total bilirubin of >1.5x to <=3x the upper limit of normal (ULN) and liver function tests (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) of <8x the ULN
Alanine aminotransferase (ALT) and aspartate transaminase (AST) ?2.5*upper limit of normal (ULN), and alkaline phosphatase and total bilirubin within normal limits
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 x institutional upper limit of normal (ULN) and total bilirubin < 1.5 x institutional ULN
Hepatic: total bilirubin less than or equal to (<=) 1.5 times the upper limit of the normal range (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=2.5*ULN.
Hepatic: total bilirubin less than or equal to (<=) 1.5*the upper limit of the normal range (ULN); alanine aminotransferase (ALT) and AST <=2.5*ULN.
Screening chemistry values of the following: Alanine aminotransferase (ALT) and aspartate transaminase (AST) ? 3.0 × upper limit of the normal (ULN), total bilirubin ? 1.5 × ULN, Creatinine ? 1.5 × ULN;
Total bilirubin =< 1.5 x upper limit of normal (ULN) except for Gilbert syndrome or cases clearly not indicative of inadequate organ function, i.e., elevation of indirect (hemolytic) bilirubin in the absence of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) abnormality
Liver dysfunction manifested by SGTP (ALT) > 5X Upper limit of normal (ULN) and/or Aspartate aminotransferase (AST) >5 X ULN and/or direct (conjugated) bilirubin > 2X ULN
Liver function: total bilirubin < 2x the upper limit of normal (unless elevated bilirubin is attributed to Gilbert's Syndrome) and alanine aminotransferase (ALT) / aspartate aminotransferase (AST) < 2.5x the upper limit of normal.
Adequate organ system functions as defined below Absolute neutrophil count>=1.0x10^9/L, hemoglobin>=8.0 g/dL, platelet>=50x10^9/L, international normalized ration (INR) <=1.5, Partial thromboplastin time <=1.5xupper limit of normal (ULN), total bilirubin <=1.25xULN, alanine aminotransferase and aspartate aminotransferase<=1.5 X ULN, serum creatinine or calculated creatinine clearance<1.2XULN >=60 mL/min for Part 1;>=50 mL/minute (min) for Part 2 if data supports loosening criteria, Albuminuria<=500 mg/24h, left ventricular ejection fraction >=50%, Troponin<=1xULN, Calcium<=1.1xULN
Impaired liver function defined as values > 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin.
Elevated liver function tests (LFTs) (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP] or bilirubin levels greater than 2.5 times the normal limit) from laboratory tests conducted within 30 days prior to surgery
Patients with liver dysfunction: total bilirubin > 2.5 mg/dl; albumin < 2.5 mg/dl; alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 5 times upper limits of normal
Patients with depressed liver function, as assessed with a screening liver function test (LFT) yielding serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than the institutional upper limit of normal; or total bilirubin greater than 2 mg/dL
Have adequate organ function, including: Hepatic: Bilirubin ?1.5 × the upper limit of normal (ULN), and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3.0 × ULN. For participants with tumor involvement of the liver, AST and ALT ?5.0 × ULN are acceptable. For participants with tumor involvement of the bone, alkaline phosphatase ?5.0 × ULN is acceptable. Renal: Serum creatinine ?2.0 × ULN. Absolute neutrophil count (ANC) ?1.0 × 109/liter (L). Hemoglobin ?9 grams per deciliter (5.58 millimoles per liter). Platelets ?90 × 109/L.
Laboratory values for hemoglobin, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and serum creatinine or calculated/measured creatinine clearance.
Patients must have adequate hepatic and renal function as evidenced by bilirubin 2.0 times the upper limit of the normal range (ULN) or lower, alanine aminotransferase (ALT) and asparate aminotransferase (AST) 3 times the ULN or lower, serum creatinine 1.5 times the ULN or lower. Patients with nonclinically significant elevations of bilirubin up to 5.0 g/dL (85500 ?mol/L) due to known or suspected Gilbert's disease are eligible; this must be documented on the medical history page of the case report form (CRF).
Impaired liver function defined as values > 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin.
Cohort 2 (mild): Bilirubin > 1-1.5 × upper limit of the normal range (ULN) or aspartate aminotransferase (AST) > ULN, but bilirubin ? ULN
Hepatic: total bilirubin less than or equal to (<=) 1.5*the upper limit of the normal range (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=2.5*ULN.
Obtained =< 21 days prior to registration: aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) < 2 x institutional upper limit of normal (ULN) within 14 days of enrollment to trial
Obtained =< 21 days prior to registration and confirmed prior to the first dose of study drug: Aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< upper limit of institutional normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal OR =< 5 x institutional upper limit of normal in cases of liver metastases
Serum aspartate aminotransferase (AST) < 5 x institutional upper limit of normal (IULN)
Aspartate aminotransferase (AST) < 5.0 x normal institutional limits within 14 days of study entry
Aspartate aminotransferase (AST) =< 3 times the institutional upper limit of normal
Aspartate aminotransferase (AST) < 4 times the upper limit of institutional normal
Performed within 14 days prior to study: Aspartate aminotransferase (AST) < 3 times the upper limits of the institutional normal
Aspartate aminotransferase (AST) =< 3 times the institutional upper limit of normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (=< 5 x institutional upper limit of normal if evidence of liver metastasis)
Aspartate aminotransferase (AST) > 1.5 x institutional upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 X institutional upper limit of normal; subjects with known liver involvement by lymphoma: AST/ALT =< 2 X institutional upper limit of normal
Aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal
Obtained =< 21 days prior to registration: Aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< 5 x institutional upper limits of normal (ULN)
Aspartate aminotransferase (AST) < 2.5 X institutional upper limit of normal
Aspartate aminotransferase (AST) =< 3 x upper limit of institutional normal
Aspartate aminotransferase (AST) < 2.5 X institutional upper limit of normal
AST < 2.5 X institutional upper limit of normal
Aspartate aminotransferase (AST) 5 x upper limit of normal (based on institutional standards)
Aspartate aminotransferase (AST) =< 1.5 x upper limit of institutional normal
Aspartate aminotransferase (AST) =< upper limit of institutional normal
Serum bilirubin ? 1.5 x upper normal limit (UNL) except patients with Gilbert's syndrome
Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) ? 2.5 x UNL but ? 5.0 x UNL in case of liver metastases; alkaline phosphatase (ALP) ? UNL but i) ? 2.5 x UNL in case of liver metastases and ii) ? 5 UNL in case of bone metastases; albumin ? 2.5 g/dl.
Total bilirubin less than 1.5 x upper normal limit (UNL)
Aspartate aminotransferase (AST) (SGOT) less than or equal to 3 x UNL
Creatinine less than 1.5 x UNL
Bilirubin =< 2 x UNL
Bilirubin =< 5X UNL;
Serum bilirubin =< 1.5 x upper normal limit (UNL), except patients with Gilbert's syndrome
Serum alanine aminotransferase (ALT) =< 2 x UNL or =< 5.0 x UNL in case of liver metastases
Serum aspartate aminotransferase (AST) =< 2 x UNL or =< 5.0 x UNL in case of liver metastases
Bilirubin =< 1.5 x UNL
Bilirubin =< 3 x UNL, values =< 2 weeks
Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x upper normal limit (UNL), alanine aminotransferase (ALT/serum glutamate pyruvate transaminase [SGPT]) =< 3 x UNL (=< 5 x UNL if liver metastases present)
Bilirubin =< 1.5 x UNL
Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x upper normal limit (UNL), alanine aminotransferase (ALT/serum glutamate pyruvate transaminase [SGPT]) =< 3 x UNL (=< 5 x UNL if liver metastases present)
Bilirubin =< 1.5 x UNL
Bilirubin =< 1.5 x UNL obtained =< 2 weeks prior to enrollment
Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x upper normal limit (UNL), alanine aminotransferase (ALT/serum glutamate pyruvate transaminase [SGPT]) =< 3 x UNL (=< 5 x UNL if liver metastases present)
Bilirubin =< 1.5 x UNL
Bilirubin < 2 x UNL
Alkaline phosphatase > UNL or > 2.5 x UNL in case of liver metastases, or > 5 x UNL in case of bone metastases.
ALT/AST > UNL or > 2.5 x UNL in case of liver metastases.
creatinine: ?2 x UNL
Bilirubin ? 1.5 x UNL ? 2 weeks
Bilirubin =< 1.5 x UNL
Total bilirubin =< 1.5 x upper normal limit (UNL)
Creatinine =< 1 x UNL
Bilirubin =< 1.5 x UNL
Aspartate aminotransferase (AST)/(serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x upper normal limit (UNL), alanine aminotransferase (ALT)/(serum glutamate pyruvate transaminase [SGPT]) =< 3 x UNL (=< 5x UNL if liver metastases present)
Bilirubin =< 1.5 x UNL
Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x upper normal limit (UNL), alanine aminotransferase (ALT/serum glutamate pyruvate transaminase [SGPT]) =< 3 x UNL (=< 5 x UNL if liver metastases present)
Bilirubin =< 1.5 x UNL
Transaminase > 3 x upper normal limit (UNL)
Total bilirubin < 1.5 mg/dL or UNL
Bilirubin =< 1.5 x UNL
Total bilirubin =< 1.5 x institutional upper normal limit (UNL) or =< 3 x institutional UNL if known Gilbert’s syndrome
Aspartate aminotransferase (AST) <2.5 x UNL
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN); if liver metastases, =< 5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 upper limits of normal (ULN)\r\n* Unless due to hepatic metastases in which case levels =< 5 x ULN are allowed
Obtained within 14 days prior to treatment start: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST must still be =< 2.5 x ULN; patients with liver metastases and AST/ALT above this limit will not be enrolled
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 × upper limit of normal (ULN); if liver metastases, then < 5 × ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if liver metastases are present
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal if no documented liver disease or < 5 x upper limit of normal if documented liver disease
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< upper limit of normal (ULN) in the absence of malignancy within the liver within 14 days of starting cycle 1 day 1 treatment
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST < 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x the ULN; for patients with documented liver metastases, AST/ALT =< 5.0 times the upper limit of normal, within 14 days before the first dose of cabozantinib
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST < 5 x ULN
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); if a patient has liver metastases, ALT and AST < 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?3.0 × the upper limit of normal(ULN), even in the presence of liver metastases.
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 times upper limit of normal (ULN) if no demonstrable liver metastases or < 5 times ULN in the presence of liver metastases obtained =< 14 days prior to study initiation
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 X upper limit of normal (ULN) or < 5 X ULN in the presence of liver metastases
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
Aspartate aminotransferase/alanine aminotransferase (AST/ALT) =< 1.5 x institutional upper limit of normal (ULN) or if liver metastasis, =< 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 2.5 × upper limit of normal (ULN). In the case of known (i.e., radiological or biopsy documented) liver metastasis, serum transaminase levels must be < 5 x ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN), < 5 x in patients with known liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 X ULN for patients with liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN) (=< 5.0 x ULN if liver metastases are involved)
(For both cohorts A and B): Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in patients with liver metastases)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) (or < 5 x ULN if liver metastasis are present)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if documented liver metastases.
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be below 2.5 x the upper limit of normal (ULN); if the patient has liver metastases, ALT and AST should be < 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN) or =< 5.0 x ULN if liver tumor is present, within 14 days start of study start
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN); for subjects with liver metastases, AST or ALT =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) without, and =< 5 x ULN with hepatic metastasis
Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) or 5.0 x upper limit of normal (ULN) in the setting of liver metastases
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x upper limit normal (ULN), or =< 5 x ULN if documented liver metastases are present
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ? 3 x upper limit of normal (ULN) (? 5.0 x ULN if liver metastases present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); for subjects with liver metastasis, ALT and AST =< 5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 × upper limit of normal (ULN); patient with liver metastases =< 5 × ULN
In the absence of liver metastases, alanine aminotransferase (AST) and aspartate aminotransferase (ALT) < 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST < 5 x ULN
ARM A COHORT 1: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN); if liver metastases are present then must be < 5 X the ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in patients with liver metastases)
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); if liver function abnormalities are due to hepatic metastasis, then AST and ALT =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN) or =< 5 x ULN for subjects with liver metastases
Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)? 2.5 × upper limit of normal (ULN) (if liver metastases are present, then?5 x ULN is allowed)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal [ULN] if liver metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) or =< 5 x ULN if known hepatic metastases
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if documented liver metastases
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if documented liver metastases.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x upper limits of normal (ULN) if liver metastases are present =< 14 days prior to registration
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) </= 2.5 x upper limit of normal\r\n(ULN); for subjects with liver metastasis, ALT and AST </= 5 x ULN within 3 weeks prior to initial treatment
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 × the upper limit of normal (ULN) if no hepatic metastases are present; >5 × ULN if hepatic metastases are present.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN); however, in the presence of liver metastases or in patients with refractory leukemias, AST and ALT must be < 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) (=< 5 x ULN in case of liver metastases)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< upper limit of normal (or < 3.0 x ULN if liver metastases are present)
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 upper limit of normal (ULN) or =< 5 x ULN if liver metastases are present
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) for patients with liver metastases and =< 2.0 x ULN for patients without liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) without, and =< 5 x ULN with hepatic metastasis
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal, unless due to liver metastases (=< 5 x ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); patients with hepatic metastases: ALT and AST =< 5 x ULN
Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ? 2.5 x Upper Limit of Normal (ULN) or ? 3.0 x ULN if liver tumor is present,
Serum aspartate aminotransferase (AST) and alanine transaminase (ALT) ? 2.5 upper limit of the normal range (ULN) (or ? 5 if hepatic metastases are present)
allow alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5x upper limit of normal (ULN) if liver metastases.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN) or =< 5 x ULN if liver involved by lymphoma
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); if liver metastases are present, =< 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN) and bilirubin =< ULN for patients without liver metastases
Hepatic: Total bilirubin ? 1.5 x the upper limit of normal (ULN). Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ? 3.0 x ULN OR ? 5.0 x ULN for patients with liver metastases.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) unless liver metastases documented; in this latter case, AST and ALT < 5 x ULN required
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 5 × upper limit of normal (ULN) for cases involving liver metastasis and ? 2.5 ×ULN for all other cases
Within 14 days of study start: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN) or =< 5.0 x ULN if liver tumor is present
If liver metastases present, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be < 3 x upper limit of normal (ULN)
Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) (Exception: =< 5 x ULN, if elevation is considered related to ASM/MCL)
Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN). If the patient has liver metastases, ALT and AST < 5 x ULN.
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) in the case of liver metastases or AST/ALT =< 1.5 x ULN in patients without liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.0 x the institutional upper limit of normal (ULN), or, in patients with known liver metastases, ?5.0 x the institutional ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal [ULN] if liver metastases are present)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal unless the liver is involved with tumor, in that case, ALT/AST must be =< 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN), or =< 5.0 x ULN if liver metastases are present
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ?2.5 x upper limit of normal (ULN; ?5 x ULN is acceptable if liver metastases are present)
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); if liver function abnormalities are due to hepatic metastasis, then AST and ALT may be =< 5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 x upper limit of normal (ULN) if no demonstrable liver metastases or >5 x ULN in the presence of liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN) (< 5 x ULN if subject has liver metastases [mets])
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN) (=< 5.0 x ULN if liver metastases are involved)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN)\r\n* NOTE: this applies to patient in the normal and renal dysfunction cohorts (N, R3 and R4); patients with elevated AST and/or ALT may be assigned to liver dysfunction cohorts
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) unless presence of hepatic metastasis in which case AST and ALT =< 5 x ULN are acceptable
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 1.5 x normal range (or =< 3.0 x upper limit of normal [ULN] if liver metastases are present)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x upper limit of normal if liver metastases present; otherwise, then =< 2.5 x upper limit
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); in patients with liver dysfunction due to hepatic metastases, AST and ALT are permitted to be =< 5 times the ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN), unless there are liver metastases in which case AST and ALT =< 5.0 x ULN
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 Upper Limit of the Normal range (ULN) (or ? 5 if hepatic metastases are present)
Aspartate transaminase (AST) and alanine aminotransferase (ALT) ? 2.5 x upper limit of normal (ULN); or ? 5.0 × ULN if liver metastases are present.
AST (Aspartate aminotransferase (GOT) and ALT (Alanine aminotransferase (GPT)) < 3.0 × ULN (upper limit of normal) or ? 5 × ULN if subject has documented liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); ALT and AST up to 5 x ULN if liver metastases present
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) of =< 2.5 x the upper limit of normal (ULN) or =< 5 x ULN if hepatic disease involvement is present as determined by the investigator
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal [ULN] if liver metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ?3.0 x the upper limit of normal (ULN); 5 x ULN if known hepatic metastases
Within 14 days prior to first study treatment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN) (unless the patient has Gilbert’s syndrome, in which case AST and ALT =< 5.0 x ULN is permitted
Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ? 3 x upper limit of normal (ULN) or AST or ALT ? 5 x ULN if liver is involved by disease process as judged by the investigator
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 upper limit of normal (ULN); if liver function abnormalities are due to the underlying malignancy, then AST and ALT must be ? 5 ULN;
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN), with the following exceptions: patients with documented liver metastases: AST and/or ALT =< 5 x ULN
Patients are eligible with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) measuring up to 5 x upper limit of normal (ULN) given the presence of liver metastasis
Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN); if liver metastases are present, =< 5 x ULN
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 2.5 × upper limit of normal (ULN); patient with liver metastases =< 5 ×ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 5 × institutional upper limit of normal (ULN) for cases involving liver metastasis and ? 2.5 ×ULN for all other cases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); except for patients with hepatic metastases: ALT and AST =< 5 x ULN
Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5x the upper limit of normal, except in the presence of known liver metastases in which case levels may be up to 5x the upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) (=< 5 x ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days)
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); patient with liver metastases =< 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 upper limit normal (ULN), or < 3 x ULN if liver metastases are present
Liver function tests (LFTs) (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) =< 3 X upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) with the following exception: patients with documented liver metastases should have AST and ALT =< 5 x ULN (obtained within 28 days prior to the first study treatment)
Moderate to severe liver failure (defined as alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 3 times upper limit of normal if no liver metastases are present; ALT or AST > 5 times upper limit of normal if liver metastases are present)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 x the upper limit of normal (ULN) if no hepatic metastases are present; >5 × ULN if hepatic metastases are present
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper limit of normal (ULN) (or =< 5 X ULN if hepatic metastases are present)
Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal range (ULN); for subjects with known liver metastases =< 5 x ULN, and alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects with known liver metastases =< 5 x ULN
DONOR: History of liver disease; a donor with a history of liver disease would be eligible if the serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) are < 2 times upper limit of normal (ULN)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN) (unless due to liver metastasis)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in patients with liver metastases)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN (institutional upper limits of normal); > 5 x ULN if liver metastasis
Total bilirubin ?1.5*the upper limit of the normal range (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5*ULN (?5*ULN if liver metastases are present).
ALT (SGPT) < 10 x upper limit of normal (ULN) for age
ALT (SGPT) < 10 x upper limit of normal (ULN) for age
PIK3CA WILD TYPE COHORT (closed 03/17/2016): AST(SGOT)/ and ALT(SGPT) =< 2.5 X institutional upper limit normal
ENDOCRINE RESISTANT AND ADJUVANT COHORT: AST(SGOT)/ and ALT(SGPT) =< 2.5 X institutional upper limit normal
SGPT (ALT) =< 5 x upper limit of normal (ULN) for age
AST (SGOT) and ALT (SGPT) ? 2.5 × institutional upper limit of normal (ULN) [? 5 × ULN in presence of liver metastases]
AST (SGOT)/ALT (SGPT) ?5 X institutional upper limit of normal if with liver metastases; ?2.5 X ULN if no liver metastases
INCLUSION CRITERIA FOR STRATUM C: ALT (SGPT) =< 3 x institutional upper limit of normal
AST/SGOT and ALT/SGPT < 2.5 x the institutional upper limit of normal (IULN).
PART II: SGOT and SGPT =< 3 x upper limit of normal (ULN)
AST (SGOT)/ALT(SGPT) (only if elevated liver function tests [LFTs] are due to disease) =< 5.0 x institutional upper limit of normal
PHASE II: AST (SGOT) =< 2.5 x institutional upper limit of normal
PHASE II: ALT (SGPT) =< 2.5 x institutional upper limit of normal
PHASE II SCLC: AST (SGOT)/ALT (SGPT) =< 2.5 X institutional upper limit of normal (=< 5X ULN if liver mets)
UROTHELIAL CARCINOMA EXPANSION COHORT: AST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal (=< 5X ULN if liver mets)
mCRPC EXPANSION COHORT: AST(SGOT)/ALT(SGPT) =< 3 X institutional upper limit of normal (=< 5X ULN if liver mets)
Transaminases (AST/SGOT and ALT/SGPT) ? 2.5 times upper limit of normal
AST(SGOT)/ALT(SGPT) > 2.5 x institutional upper limit of normal
PHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nAST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal (ULN); for subjects with liver metastases, AST or ALT =< 5 × ULN
PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nAST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal (ULN); for subjects with liver metastases, AST or ALT =< 5 × ULN
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nAST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal (ULN); for subjects with liver metastases, AST or ALT =< 5 X ULN
Newly diagnosed MCL: AST (SGOT) and ALT (SGPT) < 2 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are present
Patients must have normal organ and marrow function as defined below: leukocytes > 3,000/mcL; absolute neutrophil count >1,500/mcL; platelets > 100,000/mcL, total bilirubin < or = 2.0 mg/dL. (Does NOT apply to patients with Gilbert's Syndrome); AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal (patients with liver involvement will be allowed < or = 5.0 X institutional upper normal limit) serum creatinine < 2.0 mg/dL
ELIGIBILITY CRITERIA FOR REGISTRATION: AST(SGOT)/ALT(SGPT) =< 2.0 x institutional upper limit of normal (within one week of registration if patient postop, otherwise within two weeks of registration)
AST/SGOT and ALT/SGPT ?2.5×ULN. (upper limit of normal)
SGOT (AST)<3x upper limit of normal
Adequate hepatic function as documented by serum bilirubin< 1.5 mg/dl and SGOT and SGPT 1.5 or less x upper limit of normal.
ALT (SGPT): < 2.5 X institutional upper limit of normal
AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal (ULN) or less than or equal to 5.0 x ULN in patients with liver metastases
SGPT (ALT) and SGOT (AST) < 3 x upper limit of normal (for ALT, the upper limit of normal for all sites is defined as 45 U/L)
TREATMENT: AST (SGOT)/ALT (SGPT) =< 3 x institutional upper limit of normal
DOSE EXPANSION COHORT: AST(SGOT) ? 2.5 X institutional upper limit of normal (ULN)
Secondary Registration: AST (SGOT)/ALT (SGPT) =< 2.0 x institutional upper limit of normal
PHASE II: AST (SGOT)/ALT (SGPT) =< 3 X institutional upper limit of normal (ULN) or =< 5 X ULN if the patient has liver metastases
AST (SGOT), ALT (SGPT) ? 2.5 x upper limit of normal (ULN),
ALT (SGPT) and/or AST (SGOT) ? 3x upper limit of normal (ULN), or ? 4 x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis [EMH] related to MF);
Adequate biochemistry laboratory results (AST/SGOT and ALT/SGPT ? 3.0 x upper limit of normal; bilirubin ? 2.0 mg/dL; creatinine clearance of ? 40 mL/min).
PHASE II: AST (SGOT)/ALT (SGPT) =< 2.5 x institutional upper limit of normal
AST/SGOT and ALT/SGPT =< 2.5 x upper limit of normal (ULN) if liver metastases are present
SGOT(AST) and SGPT(ALT) < 3 x ULN (upper limit of normal)
AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal
AST(SGOT)/ALT(SGPT) ? 2.5 X institutional upper limit of normal
AST(SGOT)/ALT(SGPT) ? 2.5 X institutional upper limit of normal
EXPANSION COHORT ONLY: AST (SGOT)/ALT (SGPT) =< 2.5 X institutional upper limit of normal
AST(SGOT)/ALT(SGPT) <1.5 X institutional upper limit of normal
SGPT < 2X upper limit of normal.
Patient's ALT must be < 5 x institutional upper limit of norm ULN.
ALT (SGPT) ? 2.5 x upper limits of normal
AST, SGOT, ALT, SGPT ? 2.5 X upper limit of normal, < 5 upper limit if there are liver metastases
Serum SGOT/AST or SGPT/ALT > 3.0 x upper limit of normal (ULN)
SGOT (AST) < 3x upper limit of normal.
AST/(SGOT)/ALT(SGPT) =< 3.0 x institutional upper limit of normal (ULN) (=< 5.0 x institutional ULN with documented liver metastases)
SGOT (AST) or SGPT (ALT) < 5.0 x upper limit of normal
AST/SGOT and ALT/SGPT ?2 x Upper Limit of Normal (ULN)
AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal
AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal
AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal
Alanine aminotransferase ? 5 × upper limit of normal (ULN) for age
Alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
Obtained =< 21 days prior to registration: alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN)
Serum AST and/or alanine aminotransferase (ALT) < 3 x institutional upper limit of normal (ULN).
Obtained =< 21 days prior to registration and confirmed prior to the first dose of study drug: Alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN)
Alanine aminotransferase (ALT) < 2 x upper normal limit
Alanine aminotransferase & Asparate aminotransferase ? 2.5 x upper limit or normal
Alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
Alanine aminotransferase (ALT) > 2.5 X upper limit of normal (ULN)
Hepatic: < 5 x upper limit of normal (ULN) alanine aminotransferase (ALT).
Alanine aminotransferase (ALT) =< 3 x upper limit of normal.
Alanine aminotransferase (ALT) =< 1.5 times upper limit of normal
Alanine aminotransferase (ALT) =< 3 x upper limit of normal
Serum alanine aminotransferase (ALT) ?3 × upper limit of normal (ULN) (Grade ?1).
Alanine aminotransferase (ALT) < 2.5 x upper limit of normal
Serum alanine aminotransferase (ALT) =< 3.5 times the upper limit of normal within 21 days prior to initiation of therapy
Alanine aminotransferase (ALT) greater than 2.5 times the upper limit of normal
Alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)
Hepatic dysfunction characterized by alanine aminotransferase (ALT) >4 × upper limit of normal
Alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN) for age
Alanine aminotransferase (ALT) of =< 3 times upper limit of normal
Alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) (must be within 7 days of MLA)
Alanine aminotransferase (ALT) =< 3 times the institutional upper limit of normal
Alanine aminotransferase (ALT) < 3 times upper limit of normal
Serum alanine aminotransferase (ALT) =< 3.5 times the upper limit of normal
Serum alanine aminotransferase (ALT) less than three times the upper limit of normal (Turnstile II)
Alanine aminotransferase (ALT) =< 5 times the upper limit of normal for age
Alanine aminotransferase (ALT) less than 2 x upper limit of normal
< 3 x upper limit of normal (ULN) alanine aminotransferase (ALT)
Serum alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
Alanine aminotransferase (ALT) must be < 2 times upper limit of normal
Alanine aminotransferase (ALT) =< 2 x upper limit of normal
Alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) < 2 x upper limit of normal
Alanine aminotransferase level less than or equal to (<=) 2.5* the upper limit of normal (ULN),
Alanine aminotransferase (ALT) < 3 times the upper limit of institutional normal
At cycle 1 day 1 pre-dosing: Alanine aminotransferase level (ALT) >= 2.5 x the upper limit of normal (ULN)
Alanine aminotransferase (ALT) =< 3 x the upper limit of normal unless considered due to leukemic involvement
Performed within 14 days prior to study: Alanine aminotransferase (ALT) < 3 times the upper limits of the institutional normal
Alanine aminotransferase (ALT) =< 3 times the institutional upper limit of normal
Within 14 days of registration: Alanine aminotransferase (ALT) =< 5 x upper limit of normal
Alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) of the institutional normal reference range
Alanine Aminotransferase (ALT) < 5 times the upper limit of normal (ULN) for age;
Alanine Aminotransferase (ALT) ? 5 times the Upper Limit of Normal (ULN) for age
Alanine Aminotransferase (ALT) ? 5 times the upper limit of normal (ULN) for age.
Alanine aminotransferase (ALT) =< 2.5 times the UIHC upper limit of normal
Alanine aminotransferase (ALT) < 2.5 x institutional upper limit of normal
Alanine aminotransferase (ALT) < 3 x the upper limit of normal
Alanine aminotransferase (ALT) less than or equal to 3 times institutional upper limit of normal
Alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
Alanine aminotransferase (ALT) =< 3.5 times the upper limit of normal, unless due to chronic GVHD
Alanine aminotransferase (ALT) < institutional upper normal limit
Serum alanine aminotransferase (ALT) < 3.5 times the upper limit of normal within 30 days prior to cycle 1 day 1
Adequate liver function defined as bilirubin =< 1.5 x upper limit of normal and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
Alanine aminotransferase (ALT) =< 2.5 x the upper limit of institutional normal
Serum alanine aminotransferase (ALT) < 3.5 times the upper limit of normal within 7 days of time of consent
Alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
< 3 x upper limit of normal (ULN) alanine aminotransferase (ALT) and
Hepatic: < 5 x upper limit of normal (ULN) alanine aminotransferase (ALT)
Alanine aminotransferase (ALT) < 2.5 X institutional upper limit of normal
Alanine aminotransferase (ALT) > 2 x upper limit of normal
Alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (ULN)
Hepatic: < 3 x upper limit of normal (ULN) alanine aminotransferase (ALT)
Alanine aminotransferase (ALT) < 2 x the upper limit of normal
Alanine aminotransferase (ALT) >= 2.5 times the upper limit of normal (ULN)
Alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) obtained =< 14 days prior to registration
Alanine aminotransferase (ALT) < 3 x upper limit or normal (ULN)
Alanine aminotransferase (ALT) =< 1.5 x upper limit of normal
Alanine aminotransferase (ALT) > 2.5 times upper normal limit (unless due to disease involvement of liver)
Alanine aminotransferase (ALT) < 5 x upper limit of normal
Alanine aminotransferase (ALT) =< 5 times the upper limit of normal for age
Alanine aminotransferase (ALT) =< 5 x the upper limit of normal for age
Serum alanine transaminase (ALT) =< 2.5 x upper limit of normal
Alanine aminotransferase (ALT) <2.5 x upper limit of normal (ULN)
Serum alanine aminotransferase (ALT) =< 3.5 times the upper limit of normal within 14 days prior to randomization
Alanine aminotransferase (ALT) =< 3 times the upper limit of normal for age
Alanine aminotransferase (ALT) < 2.5 X institutional upper limit of normal
Serum transaminase (alanine aminotransferase [ALT]) equal to or =< 3 times the upper limit of the normal range
Alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) 5 x upper limit of normal (based on institutional standards)
Hepatic: < 3 x upper limit of normal (ULN) alanine aminotransferase (ALT)
Total (T.) bilirubin > 2 x upper limit of normal or alanine aminotransferase (ALT) > 4 x upper limit of normal or unresolved veno-occlusive disease
Alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)
Alanine aminotransaminase (ALT) < 5 x upper limit of normal (ULN)
The screening results for alanine aminotransferase (ALT) must be < 2 times the upper limit of normal
Alanine aminotransferase (ALT) greater than 2 x upper limit of normal (> 75 U/L)
Minocycline trial only: screening results for alanine aminotransferase (ALT), if available, must be < 3 times the upper limit of normal
Alanine aminotransferase (ALT) equal to or less than two times the upper limit of normal
Alanine aminotransferase < 3 times upper limit of normal value
Alanine aminotransferase (ALT) =< 1.5 x upper limit of institutional normal
Alanine aminotransferase (ALT) =< 2 x institutional upper limit of normal (ULN)
Alanine aminotransferase level (ALT) =< 3 x the upper limit of normal (ULN), within 30 days prior to enrollment
Alanine aminotransferase (ALT) >= 2.0 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) < 5 X institutional upper limit of normal (ULN)
Alanine aminotransferase (ALT) > 1.5 x upper limit of normal (ULN)
alanine aminotransferase <3x upper limit of normal for age (<135 U/mL)
Alanine aminotransferase (ALT) =< 1.5 times upper limit of normal
Within 14 days of registration: Aspartate aminotransferase (AST) =< 2.5 x upper limits of normal (ULN)
Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Aspartate Aminotransferase (AST) ? 3.0x the upper limit of normal (ULN)
Obtained =< 21 days prior to registration: Aspartate aminotransferase (AST) < 2.5 X ULN, with normal bilirubin; NOTE: Concomitant elevations in bilirubin and AST above 1.5 x ULN (upper limit of normal) is not permitted
Patients with aspartate aminotransferase (AST) =< 3 x upper limit of normal
Aspartate aminotransferase (AST) ? 1.5 x upper limits of normal
TREATMNET: Aspartate aminotransferase (AST) =< 3 x upper limit of normal
If requires pheresis to collect blood, aspartate aminotransferase (AST) < 1.5 upper limit of normal
Aspartate aminotransferase (AST) =< 5 x normal
Aspartate aminotransferase (AST) ? 3 x upper limit of normal
INCLUSION - PROCUREMENT: If pheresis required to collect blood:\r\n* Aspartate aminotransferase (AST) < 1.5 × upper limit normal
INCLUSION - INFUSION: Aspartate aminotransferase (AST) ? 5 x upper limit of normal
Aspartate aminotransferase (AST) < 2 x upper normal limit
Aspartate transaminase (AST) ? 3X upper limit of normal
Aspartate aminotransferase (AST) ? 3 X upper limit of normal
ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Aspartate aminotransferase (AST) ? 5 x upper limit of normal
Aspartate aminotransferase (AST) ? 3x upper limit of normal
Aspartate aminotransferase (AST) =< 2 x ULN (upper limit of normal)
Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) unless demonstrated lymphoma involvement of the liver, performed within 14 days prior to day 1 of protocol therapy
Aspartate aminotransferase (AST) =< 3 x upper limit of normal
Aspartate aminotransferase (AST) =< 2.5 upper limit of normal (ULN)
Aspartate aminotransferase (AST) < 5 x upper limit of normal
Within 4 weeks prior to the registration: aspartate aminotransferase (AST) =< 3 X upper limit of normal
To be performed within 10 business days prior to day 1: Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) unless demonstrated Hodgkin lymphoma involvement of the liver
Within 14 days prior to planned start of treatment: Aspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< 3.0 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) < 1.5 x upper limit of normal (ULN)
AT THE TIME OF INFUSION: Aspartate aminotransferase (AST) ? 5 x normal
Aspartate transaminase (AST) =< 2.5 x upper limit of normal (ULN)
TREATMENT: Aspartate aminotransferase (AST) ? 3 x upper limit of normal
Aspartate aminotransferase (AST) < 2.5 times upper limit of normal, performed within 28 days prior to registration
Within 2 weeks of enrollment: Aspartate aminotransferase (AST) =< 3 x normal range
Aspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN) (obtained =< 7 days prior to registration)
Aspartate aminotransferase (AST) < 1.5 times upper limit of normal (alkaline phosphatase and AST cannot both exceed the upper limit of normal)
Aspartate aminotransferase (AST) < 3 x upper limit of normal
Aspartate aminotransferase (AST) less than 2 x upper limit of normal
Aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< 5 x upper limit of normal
Serum aspartate aminotransferase (AST) =< 2.5 x upper limit of normal
Aspartate aminotransferase (AST) > 5x upper limit of normal
< 3 x upper limit of normal (ULN) aspartate aminotransferase (AST)
Aspartate aminotransferase (AST) =< 2 x upper limit of normal
Aspartate aminotransferase (AST) =< 5 x upper limit of normal
Aspartate transaminase (AST) =< 3 x upper limit of normal (ULN)
Within 14 days of registration: Aspartate aminotransferase (AST) =< 5 x upper limit of normal
Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) < 1.5 X upper limit of normal (ULN); patients with Gilbert's disease are exempt from this criteria
Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) without, and =< 5 x ULN with hepatic metastasis
Aspartate aminotransferase (AST) =< 5 x upper limit of normal
No history of severe prior or ongoing chronic liver disease; aspartate aminotransferase (AST) < 5 x upper limit of normal
Aspartate aminotransferase (AST) =< 1.5 X upper normal of limit (UNL)
Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) without, and =< 5 x ULN with hepatic metastasis
Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) > 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
aspartate aminotransferase (AST) less than or equal to 2.5 × upper limit of normal (ULN)*
Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)
AT THE TIME OF INFUSION: Aspartate aminotransferase (AST) ? 5 x upper limit of normal
Within 30 days prior to initiation of protocol treatment: Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< 1.5 times the upper limit of the normal range (x ULN)
Aspartate aminotransferase (AST) =< 2 x the upper limits of normal
Asparate aminotransferase (AST) < 2 x the upper limit of normal
Aspartate aminotransferase (AST) =< 2.5 x normal limits
Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) obtained =< 14 days prior to registration
Aspartate aminotransferase (AST) =< 3 x upper limit of normal
Aspartate transaminase (AST) less than or equal to 2.5 x upper limit of normal, CTCAE v 4.0 grade 1
Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal, unless liver is involved with disease or a history of Gilbert’s disease
Aspartate aminotransferase (AST) < 3 x upper normal limit (UNL)
Aspartate aminotransferase (AST) =< 1.5 x upper limit of normal
Aspartate aminotransferase (AST) < 5 x upper limit of normal
Aspartate aminotransferase (AST) =< 5 x the upper limit of normal for age
Serum aspartate transaminase (AST) =< 2.5 x upper limit of normal
Aspartate transaminase (AST) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) < 2 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< 1.5 x upper limits of normal
Aspartate aminotransferase (AST) > 3 x upper limit of normal (ULN) for the laboratory
Serum aspartate aminotransferase (AST) ? 2.0 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN), unless hepatic dysfunction is a manifestation of cGVHD
Aspartate aminotransferase (AST) =< 3 x upper limit normal
Aspartate transaminase (AST) =< 3 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< 5 x normal
Aspartate aminotransferase (AST) =< 1.8 X upper limit of normal (ULN)
Aspartate aminotransferase (AST) and ALT ?2.5 x upper limit of normal (ULN)
Aspartate aminotransaminase (AST) =< 2.5 x upper limit of normal (ULN)